Methods of using sorapinib to treat immune thrombocytopenic purpura
By adjusting the individualized dosage of solepinib, the problems of low response rate and high side effects in ITP treatment have been solved, achieving higher treatment efficacy and safety, especially for patients who are not sensitive to or intolerant to previous treatments, significantly improving platelet count and quality of life.
Patent Information
- Application Number
- CN202480090459.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-04-02
- Filing Date
- 2024-04-03
- Publication Date
- 2026-11-10
AI Technical Summary
Existing treatments for immune thrombocytopenic purpura (ITP) have low response rates and a high risk of treatment-related toxicities, especially in patients with inadequate response to previous treatments. Futatinib has a low overall response rate and significant side effects.
Individualized treatment with solepinib or its pharmaceutically acceptable salts, administered at a daily dose of approximately 100–600 mg or adjusted to an appropriate AUCtau,ss range, is available for different types and severities of ITP.
It significantly improved the response rate of ITP, reduced side effects, especially in patients who were insensitive to or intolerant of previous treatments, achieved an increase in platelet count and improved health-related quality of life, and reduced the incidence of adverse events during treatment.
Smart Images

Figure FT_1 
Figure SMS_29 
Figure SMS_32
Abstract
Description
Technical Field
[0001] This disclosure relates to a method for treating immune thrombocytopenic purpura (ITP). Background of the Invention
[0003] Primary immune thrombocytopenic purpura (ITP) is a complex hemorrhagic disorder caused by autoimmune destruction and insufficient platelet production, resulting in decreased platelet levels in peripheral blood (<100×10⁻⁶). 9 The production of autoantibodies against platelets and subsequent platelet phagocytosis are considered the core mechanisms leading to the pathogenesis of ITP, but the exact reasons behind the loss of tolerance remain unclear. The prevalence of ITP is 9.5 per 100,000 adults, with an incidence of 2–5 per 100,000 adults per year. While some ITP patients are asymptomatic or experience minor bleeding, severe mucosal bleeding can also occur. Furthermore, ITP can negatively impact patients' quality of life due to fatigue, limited activity, anxiety, and other effects.
[0004] For newly diagnosed patients with a platelet count <30×10 9 For adult ITP patients with low blood pressure, asymptomatic or mild mucosal bleeding, oral corticosteroids are recommended as first-line treatment. Most patients initially respond to glucocorticoid therapy; however, a significant proportion do not respond or experience relapse. Health-related quality of life (HRQoL) assessment during corticosteroid treatment is recommended to understand its negative impact on mental health. Second-line treatments include rituximab, thrombopoietin receptor agonists (TPO-RAs), and splenectomy; however, the potential side effects of these second-line treatments, such as infection, thrombosis, and surgical complications, are a significant risk (Blood Adv 2019; 3: 3829-66; and Blood Res 2022; 57: 112-9). Fostamatinib is currently the only Syk inhibitor approved by the US Food and Drug Administration for the treatment of ITP patients with inadequate response to prior therapy. However, the overall response rate (ORR) of flotatinib was low, with stable platelet response rates of only 18% and 16% in two placebo-controlled studies. In both studies, the incidence of hypertension and diarrhea during treatment was significantly higher in the flotatinib group (28% and 31%, respectively) compared to the placebo group (13% and 15%, respectively) (Am J Hematol. 2018 Jul; 93(7):921-930.).
[0005] Therefore, a large number of individuals with ITP still have limited sensitivity to currently available drugs or face a high risk of treatment-related toxicity. This area of medical need remains unmet. Invention Overview
[0007] This article provides the following implementation plan:
[0008] E1. Methods of treating immune thrombocytopenic purpura (ITP) in individuals in need, including administering a daily dose of approximately 100-600 mg or sufficient to reduce AUC. tau,ss Solepinib or its pharmaceutically acceptable salts are administered to individuals at a dose of approximately 600-5000 h × ng / mL.
[0009] The method of E2.E1, wherein the daily dose is about 100-400 mg, about 100-300 mg, about 300-500 mg, about 100 mg, about 200 mg, about 300 mg, about 400 mg, about 500 mg or about 600 mg.
[0010] The method of E3.E1, wherein the daily dose is about 300-500 mg, about 300 mg, about 400 mg or about 500 mg.
[0011] The method described in E4.E1, wherein the daily dose is approximately 300 mg.
[0012] The method described in E5.E1, wherein the daily dose is approximately 500 mg.
[0013] E6. The method of any of the foregoing embodiments, wherein the dose is administered once daily (QD) or in divided doses, such as twice daily (BID) or three times daily (TID).
[0014] E7. The method of any of the foregoing embodiments, wherein the dose is administered once daily (QD).
[0015] The method in E8.E1, where AUC tau,ssValues are approximately 600-4890 h × ng / mL; optionally approximately 600-800, 1000-1300, 1900-2200, or 2900-3200 h × ng / mL; optionally approximately 600-700, 1100-1200, 2000-2100, or 3000-3100 h × ng / mL; optionally approximately 640-680, 1135-1175, 2045-2185, or 3045-3085 h × ng / mL; optionally approximately 650-670, 1145-1165, 2055-2175, or 3055-3075 h × ng / mL; optionally approximately 661 h × ng / mL, or approximately 1156 h × ng / mL. ng / mL, approximately 2067 h × ng / mL, approximately 3065 h × ng / mL.
[0016] The method in E9.E1, where AUC tau,ss The values are approximately 1900-2200, approximately 2000-2100, approximately 2045-2185, approximately 2055-2175, or approximately 2067 h × ng / mL.
[0017] E10. The method of any of the foregoing embodiments, wherein the ITP is primary ITP.
[0018] E11. The method of any of the foregoing embodiments, wherein the ITP is a newly diagnosed ITP, persistent ITP, or chronic ITP.
[0019] E12. The method of any of the foregoing embodiments, wherein the ITP is chronic ITP or chronic primary ITP.
[0020] E13. The method of any of the foregoing embodiments, wherein the individual has relapsed or refractory ITP.
[0021] E14. The method of any of the foregoing embodiments, wherein the individual has previously received at least one prior anti-ITP treatment.
[0022] E15. The method of any of the foregoing embodiments, wherein the individual has an inadequate response to or intolerance to at least one prior anti-ITP treatment.
[0023] E16. The method of any of the foregoing embodiments, wherein the individual has chronic ITP and is inadequately responsive to or intolerant of at least one prior anti-ITP treatment, or has chronic primary ITP and is inadequately responsive to or intolerant of at least one prior anti-ITP treatment.
[0024] E17. The method of any of the foregoing embodiments, wherein the individual has persistent ITP and is inadequately responsive to or intolerant of at least one prior anti-ITP treatment, or has persistent primary ITP and is inadequately responsive to or intolerant of at least one prior anti-ITP treatment.
[0025] E18. The method of any of the foregoing embodiments, wherein the individual has relapsed after at least one prior anti-ITP treatment.
[0026] The method of any one of E19, E14-E18, wherein the at least one prior anti-ITP treatment is one, two, three, four, five, six, seven, eight or more prior anti-ITP treatments.
[0027] The method of any one of E20, E14-E19, wherein the at least one prior anti-ITP treatment is two, three, four, five, six, seven, eight or more prior anti-ITP treatments.
[0028] The method of any one of E21, E14-E20, wherein the at least one prior anti-ITP treatment is four, five, six, seven, eight or more prior anti-ITP treatments.
[0029] The method of any one of E22.E14-E21, wherein the at least one prior anti-ITP treatment includes at least one of first-line anti-ITP treatment, second-line anti-ITP treatment, third-line anti-ITP treatment, and further treatment, such as first-line anti-ITP treatment, second-line anti-ITP treatment, third-line anti-ITP treatment, and optional further treatment.
[0030] The method of any one of E23, E14-E22, wherein the at least one prior anti-ITP treatment includes at least one of first-line anti-ITP treatment and second-line anti-ITP treatment.
[0031] The method of any one of E24, E14-E23, wherein the at least one prior anti-ITP treatment comprises one or more (e.g., one, two, three, four, five, six, seven, eight or more, such as four, five, six, seven or more) selected from: corticosteroids (including glucocorticoids, including prednisone, prednisolone, methylprednisolone, dexamethasone and / or betamethasone), intravenous immunoglobulin therapy (IVIg), anti-D immunoglobulin, thrombopoietin (TPO) therapy (including rhTPO), thrombopoietin receptor agonist (TPO-RA) therapy (including rhTPO), and thrombopoietin receptor agonist (TPO-RA) therapy (including rhTPO). Thrombopoietin, eltrombopag, hetrombopag, avatrombopag and / or romiplostim, anti-CD20 antibody therapy (including rituximab), immunosuppressants (including cyclosporine A, azathioprine, mycophenolate mofetil, cyclophosphamide), vinca alkaloids, alenzab, danazol, dapsone, platelet transfusion, danazol / stanozolol, caffeic acid, IL-11, traditional Chinese medicine and splenectomy; optionally, at least one prior anti-ITP therapy does not include Syk inhibitors (including fotatinib).
[0032] E25. The method of any one of E14-E24, wherein the at least one prior anti-ITP treatment comprises one or more (e.g., one, two, three, four, five, six, seven, eight or more, e.g., four, five, six, seven or more) selected from the following treatments: corticosteroids (including glucocorticoids, including prednisone, prednisolone, methylprednisolone, dexamethasone and betamethasone), intravenous immunoglobulin therapy (IVIg), thrombopoietin (TPO) therapy (including rhTPO), thrombopoietin receptor agonist (TPO-RA) therapy (including thrombopoietin, eltrombopag, hetrombopag, avatrombopag and / or romiplostim), anti-CD20 antibody therapy (including rituximab), and splenectomy; optionally, the at least one prior anti-ITP treatment does not include Syk inhibitors (including fotatinib).
[0033] The method of any one of E26, E14-E25, wherein the at least one prior anti-ITP treatment includes TPO treatment and / or TPO-RA treatment.
[0034] The method of any one of E27, E14-E26, wherein the at least one prior anti-ITP treatment includes TPO treatment or TPO-RA treatment.
[0035] The method of any one of E28, E14-E26, wherein the at least one prior anti-ITP treatment comprises both TPO treatment and TPO-RA treatment.
[0036] The method of any one of E29. E14-E26, wherein the at least one prior anti-ITP treatment comprises only one drug of TPO / TPO-RA treatment.
[0037] The method of any one of E30, E14-E26, wherein the at least one prior anti-ITP treatment comprises at least two drugs of TPO / TPO-RA treatment.
[0038] The method of any one of E31, E14-E26, wherein the at least one prior anti-ITP treatment comprises 2, 3, 4, 5 or more drugs for TPO / TPO-RA treatment.
[0039] The method of any one of E32, E14-E26, wherein the at least one prior anti-ITP treatment comprises one or more active agents selected from recombinant human thrombopoietin, eltrombopag, hetrombopag, avatrombopag, and romiplostim.
[0040] The method of any one of E33, E26-E31, wherein the TPO / TPO-RA treatment drug comprises one or more active agents selected from recombinant human thrombopoietin, eltrombopag, hetrombopag, avatrombopag, and romiplostim.
[0041] The method of any one of E34, E14-E33, wherein the at least one prior anti-ITP treatment comprises anti-CD20 antibody treatment.
[0042] The method of any one of E35, E14-E34, wherein the at least one prior anti-ITP treatment includes rituximab.
[0043] The method of any one of E36, E14-E35, wherein the at least one prior anti-ITP treatment includes splenectomy.
[0044] The method of any one of E37, E14-E36, wherein the at least one prior anti-ITP treatment includes emergency anti-ITP treatment.
[0045] E38. The method of any of the foregoing embodiments, wherein the individual has a platelet count of less than 30 × 10⁻⁶ prior to treatment with solepinib or a pharmaceutically acceptable salt thereof. 9 .
[0046] E39. The method of any of the foregoing embodiments, wherein the individual has a platelet count of less than 15 × 10⁻⁶ prior to treatment with solepinib or a pharmaceutically acceptable salt thereof. 9 .
[0047] E40. The method of any of the foregoing embodiments, wherein the individual has a platelet count greater than 15 × 10⁻⁶ prior to treatment with sorapinib or its pharmaceutically acceptable salts. 9 / L and less than 30×10 9 / L.
[0048] E41. The method of any of the foregoing embodiments, wherein the individual has a hemoglobin level ≥100 g / L and >1.5 × 10⁻⁶ g / L prior to treatment with sorapinib or a pharmaceutically acceptable salt thereof. 9 Neutrophil count / L.
[0049] E42. The method of any of the foregoing embodiments, wherein the individual has had persistent ITP for ≥3, 4, 5, 6 or more months but less than 1 year, or has had persistent ITP for ≥3 months but less than 1 year, or has had chronic ITP for ≥1 year prior to treatment with solepinib or its pharmaceutically acceptable salts.
[0050] E43. The method of any of the foregoing embodiments, wherein the individual has an ITP bleeding scale (IBLS) score of 0 or 1 prior to treatment with sorapinib or its pharmaceutically acceptable salts, and / or has had chronic ITP for ≥3 years.
[0051] E44. The method of any of the foregoing embodiments, wherein the individual has a WHO bleeding scale score of 0 or 1 and / or has chronic ITP for ≥3 years prior to treatment with sorapinib or its pharmaceutically acceptable salts.
[0052] E45. The method of any of the foregoing embodiments, wherein the individual has a WHO bleeding scale score of 0 or 1 prior to treatment with sorapinib or its pharmaceutically acceptable salt.
[0053] E46. The method of any of the foregoing embodiments, wherein the individual is unresponsive to sorapinib or a pharmaceutically acceptable salt thereof during the first 12 weeks of treatment.
[0054] E47. The method of any of the foregoing embodiments, wherein the individual is an adult.
[0055] E48. The method of any of the foregoing embodiments, wherein the individual is of Asian descent.
[0056] E49. The method of any one of E1-E47, wherein the individual is a non-Asian population, such as a Western population, an American population, a European population, a Caucasian population, an Oceanian population (Australasian population), and / or an African population.
[0057] E50. The method of any of the foregoing embodiments, wherein the dose of solepinib or a pharmaceutically acceptable salt thereof administered is sufficient to cause AUC tau,ss The value reached approximately 2067 h × ng / mL.
[0058] E51. The method of any one of E1-E49, wherein solepinib or a pharmaceutically acceptable salt thereof is administered at a daily dose of about 100-300 mg, such as about 100 mg, about 200 mg or about 300 mg, or sufficient to cause AUC tau,ss Administer a dose with a value of approximately 2055-2175 h × ng / mL (e.g., 2067 h × ng / mL).
[0059] E52. The method of any one of E1-E49, wherein solepinib or a pharmaceutically acceptable salt thereof is administered at a daily dose of about 300 mg, or sufficient to cause AUC tau,ss Administer a dose with a value of approximately 2055-2175 h × ng / mL (e.g., 2067 h × ng / mL).
[0060] E53. The method of any one of E1-E49, wherein solepinib or a pharmaceutically acceptable salt thereof is administered at a daily dose of about 100-300 mg, such as about 100 mg, about 200 mg or about 300 mg, or sufficient to cause AUC tau,ss The dose is administered at a value of approximately 2055-2175 h × ng / mL (e.g., 2067 h × ng / mL), and the individuals mentioned are Asian populations.
[0061] E54. The method of any one of E1-E49, wherein solepinib or a pharmaceutically acceptable salt thereof is administered at a daily dose of about 300 mg, or sufficient to cause AUC tau,ss The dose is administered at a value of approximately 2055-2175 h × ng / mL (e.g., 2067 h × ng / mL), and the individuals mentioned are Asian populations.
[0062] E55. The method of any one of E1-E49, wherein solepinib or a pharmaceutically acceptable salt thereof is administered at a daily dose of about 300-500 mg, such as about 300 mg, about 400 mg or about 500 mg, or sufficient to cause AUC tau,ss Administer a dose with a value of approximately 2055-2175 h × ng / mL (e.g., 2067 h × ng / mL).
[0063] E56. The method of any one of E1-E49, wherein solepinib or a pharmaceutically acceptable salt thereof is administered at a daily dose of about 500 mg, or sufficient to cause AUC tau,ss Administer a dose with a value of approximately 2055-2175 h × ng / mL (e.g., 2067 h × ng / mL).
[0064] E57. The method of any one of E1-E49, wherein solepinib or a pharmaceutically acceptable salt thereof is administered at a daily dose of about 300-500 mg, such as about 300 mg, about 400 mg or about 500 mg, or sufficient to cause AUC tau,ss The dose is administered at a value of 2055-2175 h × ng / mL (e.g., 2067 h × ng / mL), and the individuals mentioned are non-Asian populations, such as Western populations, American populations, European populations, Caucasian populations, Oceanian populations (Australasian-like populations), and / or African populations.
[0065] E58. The method of any one of E1-E49, wherein solepinib or a pharmaceutically acceptable salt thereof is administered at a daily dose of about 500 mg, or sufficient to cause AUC tau,ss The dose is administered at a value of 2055-2175 h × ng / mL (e.g., 2067 h × ng / mL), and the individuals mentioned are non-Asian populations, such as Western populations, American populations, European populations, Caucasian populations, Oceanian populations (Australasian-like populations), and / or African populations.
[0066] E59. The method of any of the foregoing embodiments, wherein the dose of sorapinib or a pharmaceutically acceptable salt thereof is reduced during treatment in the following circumstances: (1) During treatment, an individual's platelet count is ≥250 ×10⁻⁶. 9 Platelets count of approximately 400 × 10⁹ for about two weeks, or a platelet count ≥ 400 × 10⁹ at any time. 9 / L; (2) The individual received combined anti-ITP therapy and had a platelet count ≥100×10⁶ during the treatment period. 9 / L for approximately 4 weeks, or a platelet count ≥250×109 / L lasts approximately 2 weeks; or (3) Individuals experience drug-related adverse events.
[0067] E60. The method of any one of E4, E52 and E54, wherein during treatment the said daily dose of sorapinib or a pharmaceutically acceptable salt thereof is reduced to 200 mg, and optionally further reduced to 100 mg daily, in the following condition: (1) During treatment, an individual's platelet count is ≥250 ×10⁻⁶. 9 Platelets count of approximately 400 × 10⁹ for about two weeks, or a platelet count ≥ 400 × 10⁹ at any time. 9 / L individuals; (2) Individuals receiving concurrent anti-ITP therapy and having a platelet count ≥100×10⁶ during treatment. 9 / L for approximately 4 weeks, or a platelet count ≥250×10 9 / L lasts approximately 2 weeks; or (3) Individuals experience drug-related adverse events.
[0068] E61. The method of any one of E4, E52 and E54, wherein during treatment the said daily dose of sorapinib or a pharmaceutically acceptable salt thereof is successively reduced to 200 mg and 100 mg in the following situations: (1) Individuals with a platelet count ≥250 ×10⁻⁶ within two weeks 9 Platelets, or a platelet count ≥400 × 10⁹ / L at any time during treatment. 9 / L; (2) Individuals receiving concurrent anti-ITP therapy and having a platelet count ≥100×10⁶ during treatment. 9 / L for 4 weeks, or platelet count ≥250×10 9 / L up to 2 weeks; or (3) Individuals experience drug-related adverse events.
[0069] E62. The method of any one of E5, E56 and E58, wherein during treatment, the said daily dose of sorapinib or a pharmaceutically acceptable salt thereof is successively reduced to 400 mg, and optionally further reduced to 300 mg, in the following situations: (1) During treatment, an individual's platelet count is ≥250 ×10⁻⁶. 9 Platelets count of approximately 400 × 10⁹ for about two weeks, or a platelet count ≥ 400 × 10⁹ at any time. 9 / L; or (2) Individuals receiving concurrent anti-ITP therapy and having a platelet count ≥100×10⁶ during treatment. 9 / L for approximately 4 weeks, or a platelet count ≥250×10 9 / L lasts approximately 2 weeks; or (3) Individuals experience drug-related adverse events.
[0070] E63. The method of any one of E5, E56 and E58, wherein during treatment the said daily dose of sorapinib or a pharmaceutically acceptable salt thereof is successively reduced to 400 mg and 300 mg in the following situations: (1) Individuals with a platelet count ≥250 ×10⁻⁶ within two weeks 9 Platelets, or a platelet count ≥400 × 10⁹ / L at any time during treatment. 9 / L; or (2) Individuals receiving concurrent anti-ITP therapy and having a platelet count ≥100×10⁶ during treatment. 9 / L for 4 weeks, or platelet count ≥250×10 9 / L up to 2 weeks; or (3) Individuals experience drug-related adverse events.
[0071] E64. The method of any of the foregoing embodiments, wherein solepinib or a pharmaceutically acceptable salt thereof is administered once daily (QD) or twice daily in divided doses (BID).
[0072] E65. The method of any of the foregoing embodiments, wherein solepinib or its pharmaceutically acceptable salt is administered orally.
[0073] E66. The method of any of the foregoing embodiments, wherein solepinib or a pharmaceutically acceptable salt thereof is administered as a monotherapy or in combination with one or more other therapeutic agents.
[0074] E67. The method of any of the foregoing embodiments, wherein solepinib or a pharmaceutically acceptable salt thereof is administered in combination with concomitant anti-ITP treatment, for example, in parallel with a concomitant anti-ITP treatment.
[0075] E68. The method of any of the foregoing embodiments, wherein the individual has been receiving a stable dose of concomitant anti-ITP treatment.
[0076] E69. The method of any one of E66-E68, wherein the other therapeutic agent or concomitant anti-ITP treatment is a combination drug selected from the following: corticosteroids, TPO-RA, danazol and immunosuppressants.
[0077] The method of any one of E70, E66-E68, wherein the other therapeutic agent or combined anti-ITP treatment is a combination drug selected from the following: corticosteroids and TPO-RA.
[0078] The method of any one of E71, E66-E68, wherein the other therapeutic agent or concomitant anti-ITP treatment is a combination drug selected from the following: corticosteroids, danazol and immunosuppressants.
[0079] The method of any one of E72, E66-E68, wherein the other therapeutic agent or combined anti-ITP treatment is not an emergency treatment.
[0080] E73. The method of any of the foregoing embodiments, the method comprising administering solepinib or a pharmaceutically acceptable salt thereof to an individual for at least 2 weeks or more, for example, at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more weeks, or at least 1, 2, 3 or more years.
[0081] E74. The method of any of the foregoing embodiments, the method comprising administering solepinib or a pharmaceutically acceptable salt thereof to an individual for at least 12 or more weeks, for example, at least 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more weeks.
[0082] E75. The method of any of the foregoing embodiments, the method comprising administering solepinib or a pharmaceutically acceptable salt thereof to an individual for at least 1, 2, 3 or more years.
[0083] E76. The method of any of the foregoing embodiments, wherein the individual, after treatment with sorapinib or its pharmaceutically acceptable saline, has (relative to pre-treatment) a sustained response (including improved sustained response rate (DRR)), an improved overall response (including improved overall response rate (ORR)), an improved platelet count (e.g., improved median platelet count), a rapid onset of action or improved time to response (TTR), a reduction in the incidence or severity of bleeding, including a reduction in the WHO Bleeding Scale, a reduction in the frequency of ≥ grade 3 bleeding, improved hemoglobin levels, long-term remission of ITP, improved health-related quality of life (HRQoL) (e.g., in terms of physical function, energy / fatigue, role limitations due to physical health, role limitations due to emotional problems, emotional health and / or general health status), reduced use of emergency treatments (e.g., emergency medications) and / or reduced or interrupted baseline concomitant anti-ITP treatment, and / or is safe and tolerable over time, with an optional low risk of gastrointestinal toxicity.
[0084] E77. The method of any of the foregoing embodiments, wherein the individual has a sustained response (including improved DRR) after treatment with sorapinib or its pharmaceutically acceptable salt.
[0085] E78. The method of any of the foregoing embodiments, wherein the individual has an improved overall response (including an improved ORR) after treatment with sorepinib or its pharmaceutically acceptable salt, for example, an improved overall response rate within 0-12 weeks or 0-24 weeks.
[0086] E79. The method of any of the foregoing embodiments, wherein the individual, after treatment with sorapinib or a pharmaceutically acceptable salt thereof, has an improved platelet count (e.g., an improved median platelet count), including an increase in platelet count, e.g., an increase of at least 10 × 10⁻⁶ compared to pre-treatment levels. 9 / L, 15×10 9 / L, 20×10 9 / L, 25×10 9 / L, 30×10 9 / L, 35×10 9 / L, 40×10 9 / L, 45×10 9 / L, 50×10 9 / L, 60×10 9 / L, 70×10 9 / L, 80×10 9 / L, 90×10 9 / L or 100×10 9 / L, for example, an increase of approximately 10 × 10 9 / L to 100×10 9 / L or approximately 25×10 9 / L to 75×10 9 / L or approximately 30×10 9 / L to 60×10 9 / L, or a platelet count of at least 30 × 10⁹ / L. 9 / L, 40×10 9 / L, 50×10 9 / L, 60×10 9 / L, 70×10 9 / L, 80×10 9 / L, 90×10 9 / L, 100×10 9 / L、110×10 9 / L, 120×10 9 / L, 130×10 9 / L, 140×10 9 / L, 150×10 9 / L, 180×10 9 / L, 200×10 9 / L or 250×10 9 / L, and / or maintain an improved platelet count for at least approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or more weeks.
[0087] E80. The method of any of the foregoing embodiments, wherein the individual, after treatment with sorepinib or a pharmaceutically acceptable salt thereof, has improved hemoglobin levels, including an increase relative to pre-treatment hemoglobin levels, for example at least 10 g / L, 15 g / L, 20 g / L, 25 g / L, 30 g / L, 35 g / L, 40 g / L, 45 g / L, or 50 g / L, or a hemoglobin level reaching at least 100 g / L, 110 g / L, 115 g / L, 120 g / L, 125 g / L, 130 g / L, 135 g / L, 140 g / L, 145 g / L, or 150 g / L.
[0088] E81. The method of any of the foregoing embodiments, wherein the individual, after treatment with sorapinib or its pharmaceutically acceptable salt, has a rapidly onset or improved TTR, a reduced incidence or severity of bleeding, including a reduction in the WHO bleeding scale, and / or a reduction in the frequency of bleeding grade ≥3.
[0089] E82. The method of any of the foregoing embodiments, wherein the individual, after treatment with sorapinib or its pharmaceutically acceptable salt, has improved health-related quality of life (HRQoL), for example, improvements in physical function, energy / fatigue, role limitations due to physical health, role limitations due to emotional problems, emotional health, and / or general health.
[0090] E83. The method of any of the foregoing embodiments, wherein the individual has improved health-related quality of life (HRQoL) in terms of physical function and energy / fatigue after treatment with sorapinib or its pharmaceutically acceptable salt.
[0091] E84. The method of any of the foregoing embodiments, wherein the individual reduces the use of emergency treatment (e.g., emergency medication) and / or reduces or interrupts baseline concomitant anti-ITP treatment after treatment with sorepinib or its pharmaceutically acceptable salt.
[0092] E85. The method of any of the foregoing embodiments, wherein a pharmaceutically acceptable salt of solepinib is solepinib acetate.
[0093] E86. An article comprising:
[0094] Solepinib or its pharmaceutically acceptable salts, and
[0095] The product information leaflet includes instructions for the use of sorapinib or a pharmaceutically acceptable salt thereof for the treatment of immune thrombocytopenic purpura (ITP) in individuals in need, wherein the instructions indicate that sorapinib or a pharmaceutically acceptable salt thereof shall be administered in accordance with the method defined in any of the foregoing embodiments.
[0096] E87. Solepinib or a pharmaceutically acceptable salt thereof used in methods as defined in any of E1-E85.
[0097] E88. Solepinib or a pharmaceutically acceptable salt thereof, for use in individuals of need at a daily dose of about 100-600 mg or sufficient to induce AUC. tau,ss A dose of approximately 600-5000 h × ng / mL is used to treat immune thrombocytopenic purpura (ITP), wherein the treatment is performed according to any of the methods in E1-E85.
[0098] E89. A pharmaceutical composition comprising solepinib or a pharmaceutically acceptable salt thereof, for the treatment of immune thrombocytopenic purpura (ITP) in an individual in need as defined in any one of E1-E85.
[0099] E90. A pharmaceutical composition comprising solepinib or a pharmaceutically acceptable salt thereof, for use in individuals of need at a daily dose of about 100-600 mg or sufficient to induce an AUC. tau,ss A dose of approximately 600-5000 h × ng / mL is used to treat immune thrombocytopenic purpura (ITP), wherein the treatment is performed according to any of the methods in E1-E85.
[0100] E91. Use of solepinib or a pharmaceutically acceptable salt thereof in the preparation of a medicament intended for use in individuals of need at a daily dose of about 100-600 mg or sufficient to achieve an AUC of tau,ss A dose of approximately 600-5000 h × ng / mL is used to treat immune thrombocytopenic purpura (ITP), wherein the treatment is performed according to any of the methods in E1-E85.
[0101] E92. Solepinib or a pharmaceutically acceptable salt thereof in a daily dose of about 100-600 mg or sufficient to cause AUC tau,ss Used in treating individuals with immune thrombocytopenic purpura (ITP) at doses of approximately 600-5000 h × ng / mL, wherein said treatment is performed according to any of the methods in E1-E85.
[0102] Each embodiment and feature described in this disclosure should be understood as being able to be combined with each other in any way, and all technical solutions obtained by such (or such) combinations are included within the scope of this disclosure as if each technical solution obtained by such (or such) combinations were specifically and separately listed, unless the context clearly shows otherwise. Brief description of the attached diagram
[0104] Figure 1 The median platelet count over time is shown during a 24-week double-blind treatment period. Invention Details
[0106] definition
[0107] Unless otherwise stated, the following terms shall be understood to have the following meanings:
[0108] As used herein (including the claims), singular terms (e.g., “a,” “an,” and “the”) include their corresponding plural forms, unless the context clearly indicates otherwise.
[0109] As used herein, the term “about” means approximately, within its range, roughly, or around. When the term “about” is used in conjunction with a numerical range, it modifies the range or the numerical value by extending the boundaries above and below the given numerical value. Typically, the term “about” is used herein to indicate a range of variation of ≤ ±20%, for example, ± 10%, ± 5%, ± 1%, or ±0.1%, which is suitable for the methods of this disclosure.
[0110] The terms “including,” “comprising,” and “containing” should be interpreted inclusively rather than exclusively, meaning “including but not limited to.” Similarly, the terms “including,” “comprising,” and their variations should be interpreted inclusively unless the context explicitly prohibits such interpretation. For example, a method that “includes” X can consist of only X, or it can include other elements, such as X+Y.
[0111] The term “and / or” should be interpreted as meaning that one or more of the listed elements or conditions may exist individually or in combination, without necessarily requiring all elements or conditions to exist simultaneously.
[0112] As used in this article, "immune thrombocytopenic purpura" or "ITP" refers to an autoimmune disease or disorder in which pathogenic IgG destroys platelet-producing cells (megakaryocytes) and circulating platelets (coagulation cells). Pathogenic IgG drives disease progression in multiple modalities: they accelerate platelet clearance, inhibit platelet production, directly induce platelet killing, and interfere with the ability of platelets to perform their coagulation function. Primary ITP is idiopathic and unrelated to any other disease, while secondary ITP is associated with an underlying autoimmune disease or infection (such as HCV or HIV infection). Affected patients typically have a platelet count < 30 × 10⁻⁶. 9 There is a risk of spontaneous bleeding when the platelet count is < 10 × 10⁹ / L, including when the platelet count is < 10 × 10⁹ / L. 9 / L indicates life-threatening bleeding. ITP can be classified into acute and chronic types. ITP can be classified into newly diagnosed ITP, persistent ITP, or chronic ITP. Newly diagnosed ITP refers to ITP within three months of initial diagnosis. Persistent ITP refers to ITP lasting 3 to 12 months from the date of diagnosis. Chronic ITP refers to ITP lasting more than 12 months from the date of diagnosis. Rodeghiero F et al., Blood 113(11):2386-2393 (2009). ITP also includes relapsed or refractory ITP and severe ITP; as well as persistent ITP, chronic ITP, or severe ITP that has recently relapsed and / or worsened due to inadequate response to at least one prior anti-ITP therapy (such as first-line anti-ITP therapy, second-line anti-ITP therapy, and / or third-line anti-ITP therapy).
[0113] As used herein, the term "treatment" refers to therapeutic treatment in which the aim is to slow or alleviate undesirable physiological changes or disease during treatment, or to provide beneficial or desired clinical outcomes. For the purposes of this invention, beneficial or desired clinical outcomes include, but are not limited to, one or more of the following: reducing one or more symptoms caused by the disease, alleviating the severity of the disease, stabilizing the disease (e.g., preventing or delaying disease exacerbation), delaying or slowing disease progression, improving the disease state, reducing the dosage of one or more other medications required to treat the disease, and / or improving quality of life.
[0114] Treatment may involve therapeutic agents, also referred to herein as “medications” or “drugs,” which may be designed to help achieve beneficial or desired clinical outcomes. Therapeutic agents or drugs can be administered via a variety of routes, including at least intravenous injection and oral administration. The term “oral” in relation to the administration of a therapeutic agent or drug means that the therapeutic agent or drug is administered through an oral passage, such as the mouth.
[0115] As used herein, “anti-ITP therapy” or “ITP treatment” refers to any treatment generally considered effective for treating ITP. In some embodiments, the anti-ITP therapy conforms to guidelines issued by national or international authorities (such as the American Society of Hematology). In some embodiments, “anti-ITP therapy” includes adopting a wait-and-see approach, i.e., when an individual’s platelet count is > 30 x 10⁻⁶. 9 In cases where there is no bleeding and / or no signs of bleeding, clinical and laboratory parameters are monitored without therapeutic intervention. In some implementations, “anti-ITP therapy” includes therapeutic intervention with one or more anti-ITP drugs discussed herein and / or splenectomy. For anti-ITP drugs involving intervention with one or more anti-ITP drugs, said one or more anti-ITP drugs may be administered at one or more times, and in the case of multiple times, each compound may be administered independently as planned or as needed.
[0116] The terms “anti-ITP drug,” “anti-ITP activator,” or “anti-ITP medication” used in this article are used interchangeably to refer to any compound generally considered effective in the treatment of ITP, including standard anti-ITP drugs. In 2019, the American Society of Hematology published its “Guideline for the Treatment of ITP” (Blood Adv (2019) 3 (23): 3829-3866.). Any compound or class of compounds mentioned in this guideline is considered a “standard anti-ITP drug” and falls within the definition of “anti-ITP drug.” Similarly, the updated international consensus report on the investigation and management of primary immune thrombocytopenic purpura in 2019 (Blood Advances, Vol. 3, No. 22 (2019): 3780-3817) and the Chinese Guidelines for the Diagnosis and Treatment of Primary Immune Thrombocytopenic Purpura in Adults (2020 Edition) (Chin J Hematol, August 2020, Vol. 41, No. 8) provide examples of compounds considered to meet this definition. This includes, but is not limited to, corticosteroids (including glucocorticoids such as prednisone, prednisolone, dexamethasone, methylprednisolone, and betamethasone), intravenous immunoglobulins, anti-D immunoglobulins, anti-CD20 antibodies (including rituximab), platelet stimulants (including TPO therapeutics such as recombinant human thrombopoietin (rhTPO), TPO-RA (e.g., eltrombopag, hetrombopag, avatrombopag, and romiplostim), and immunosuppressants (e.g., cyclosporine A, azathioprine, and mycophenolate mofetil). The following are listed: mofetilb, vincaalkaloids, alemtuzumab, danazol, dapsone, platelet transfusions, danazol / stanozolol, caffeic acid, IL-11, traditional Chinese medicine, and any combination thereof. Needless to say, with scientific advancements, new compounds will be added to this definition.
[0117] The term "treatment line" or "line of treatment" used in connection with the treatment methods described in this article refers to one or more cycles of a planned treatment regimen, which may consist of one or more planned cycles of single-agent therapy or combination therapy, and a sequence of treatments administered in a planned manner. The initiation of a new treatment line is considered to be made if the planned course of treatment is adjusted due to disease progression, relapse, or toxicity, and other therapeutic agents or drugs (alone or in combination). The interruption of a planned observation period due to the need for additional treatment for the disease is also considered to be the start of a new treatment line.
[0118] "First-line" in the context of first-line treatment or therapy for a disease or condition refers to the initial or first-line treatment or therapy for the stated disease or condition. "Second-line" in the context of second-line treatment or therapy for a disease or condition refers to treatment or therapy administered after initial treatment (first-line treatment) for the stated disease or condition, typically because the initial treatment was ineffective or insufficiently effective, no longer effective, or had side effects. For example, "first-line treatment" for ITP includes, but is not limited to, corticosteroids (including glucocorticoids such as prednisone, prednisolone, dexamethasone, methylprednisolone, and betamethasone) and / or intravenous immunoglobulins, while "second-line treatment" for ITP includes one or more TPO-RAs (e.g., romiplostim, eltrombopag, and avatrombopag), anti-CD20 antibodies including rituximab, splenectomy, immunosuppressants (e.g., cyclosporine A, azathioprine, mycophenolate mofetil, cyclophosphamide), and / or TPO therapeutics (such as rhTPO).
[0119] As used in this article, “thrombopoietin therapy” or “TPO therapy” refers to any therapeutic intervention using an agent that has similar biological function to endogenous TPO. For example, the active agent could be recombinant human thrombopoietin (rhTPO), a full-length glycosylated TPO produced by Chinese hamster ovary cells.
[0120] As used herein, the terms “TPO receptor agonist therapy” or “TPO-RA therapy” refer to any therapeutic intervention using one or more TPO receptor agonists. In some implementations, a “TPO receptor agonist” or “TPO-RA” is an agent that promotes the biological function of the TPO receptor to some extent, typically by binding to and enhancing the activity of the TPO receptor. Examples of TPO receptor agonists specifically considered herein include eltrombopag, hetrombopag, avatrombopag, and romiplostim.
[0121] The term “TPO / TPO-RA treatment” as used in this article refers to TPO treatment and / or TPO-RA treatment.
[0122] As used in this article, "corticosteroids" refers to any of several synthetic or natural substances that have the common chemical structure of steroids and can mimic or enhance the effects of natural corticosteroids (such as glucocorticoids). Examples of glucocorticoids include prednisone, prednisolone, methylprednisolone, dexamethasone, and betamethasone.
[0123] As used herein, the term "CD20 antibody" or "anti-CD20 antibody" refers to an antibody that specifically binds to the antigen CD20, particularly human CD20. In some embodiments, the previously administered anti-CD20 antibody includes rituximab.
[0124] As used herein, the terms “relapsed or refractory” or “R / R” disease, unless otherwise stated, refer to relapsed and / or refractory disease. “Refractory” disease is defined as disease that progresses during treatment, fails to achieve an objective response to prior treatment, or progresses again after the completion of treatment. “Relapsed” or “recurrent” disease is defined as disease that previously responded to treatment but worsened after the completion of treatment. For example, “relapsed” or “recurrent” ITP may include the following clinical outcome: platelet count <30 × 10⁻⁶ again. 9 / L, or a platelet count <2 times the baseline value, or bleeding after effective anti-ITP treatment. "Refractory" ITP includes the disease in individuals who develop severe ITP after splenectomy.
[0125] As used herein, the term “response” means an outcome that can be assessed using any endpoint that indicates individual benefit, including but not limited to: (1) an increase in the patient’s platelet count; (2) an improvement in time to onset; (3) a reduction in the incidence or severity of bleeding (e.g., a reduction in the proportion of WHO bleeding, a reduction in the frequency of bleeding ≥ grade 3); (4) the achievement of long-term ITP remission; (5) a reduction in the incidence of patients requiring emergency treatment; (6) a reduction or interruption of baseline concomitant anti-ITP therapy; (7) partial relief of one or more symptoms associated with previously untreated ITP; and / or (8) an improvement in quality of life, including health-related quality of life (HRQoL).
[0126] As used herein, the term "inadequate response" refers to the presence of signs and / or symptoms of persistent active disease (such as ITP) despite prior treatment with one or more treatments, such as previous anti-ITP therapy, such as corticosteroids (e.g., glucocorticoids), anti-CD20 antibody therapy, TPO, and / or TPO-RA. An inadequate response can be defined by specific clinical endpoints or other endpoints, as described in the examples provided herein. An inadequate response as described herein includes outcomes where no identifiable response to treatment was observed (e.g., no response), and outcomes where a response to treatment was observed but considered insufficient or suboptimal to meaningful symptom or disease-treating relief. Inadequate responses include refractory responses and relapses. In some embodiments, an "inadequate response" or "no response" to prior anti-ITP therapy may be defined by the following clinical outcome: an individual's platelet count has not increased to a level sufficient to prevent clinically significant bleeding following prior anti-ITP therapy, e.g., a platelet count <30 × 10⁻⁶. 9 / L, or platelet count < 2 times the baseline value.
[0127] As used herein, the terms “intolerance” or “intolerant” refer to a situation where a patient experiences excessive side effects from at least one line of treatment or even all available therapies for ITP, resulting in an inappropriate benefit / risk ratio. Intolerance may require discontinuation of treatment for a period of time or indefinitely.
[0128] The term "overall response rate" as used in this article refers to the rate of platelet count ≥50 × 10⁻⁶ during the treatment period, without emergency treatment. 9 Percentage of patients with / L (n (%)).
[0129] The term "sustained response rate" as used in this article refers to a platelet count ≥50 × 10⁶ in at least four out of six bi-weekly follow-ups during the 14th to 24th week (inclusive) period of treatment. 9 Percentage of patients with / L (n(%))
[0130] The term "health-related quality of life (HRQoL)" used in this article is generally considered to be a multidimensional assessment of how disease and treatment affect a patient's overall functioning and health. The U.S. Food and Drug Administration (FDA) officially defines HRQoL as "a multi-domain concept representing a patient's overall perception of the physiological, psychological, and social impacts of disease and treatment on their life."
[0131] As used in this article, “SF-36” refers to the widely used Medical Outcomes Health Survey “Short Form-36”, which is used as a tool to monitor patient medical care outcomes. See Tarlov AR et al., JAMA 1989, 262(7): 925-30; Linde, L. et al., J Rheumatol, 35 (2008), pp. 1528-1537.
[0132] The term "concomitant anti-ITP therapy" refers to one or more anti-ITP treatments administered concurrently with a primary treatment agent (such as sorapinib or a pharmaceutically acceptable saline disclosed herein). In some embodiments, the concomitant anti-ITP therapy is selected from corticosteroids (including glucocorticoids), danazol, immunosuppressants (including azathioprine, cyclosporine A, or mycophenolate mofetil), or TPO-RAs. In some embodiments, the concomitant anti-ITP therapy is selected from corticosteroids (including glucocorticoids), danazol, or immunosuppressants (including azathioprine, cyclosporine A, or mycophenolate mofetil). In some embodiments, the concomitant anti-ITP therapy is selected from corticosteroids (including glucocorticoids) or TPO-RAs. In some embodiments, the concomitant anti-ITP therapy is an emergency treatment.
[0133] As used herein, the term "concomitantly" refers to the administration of two or more therapeutic agents at sufficiently close intervals that their respective therapeutic effects overlap over time. Therefore, concurrent administration includes an administration regimen in which one or more active agents are administered after discontinuation of one or more other active agents. In some embodiments, concurrent administration can be parallel administration, sequential administration, and / or simultaneous administration.
[0134] As used herein, the terms “patient,” “subject,” or “individual” refer to a warm-blooded animal. In one implementation, a patient is a human being. It may be a person who has been diagnosed with a disease or disorder and requires treatment, as disclosed herein. For the purposes of this document, the patient or individual is a person who is experiencing, has experienced, or may experience one or more signs, symptoms, or other indicators of ITP; or has a newly diagnosed ITP, persistent ITP, or chronic ITP; or has relapsing ITP, refractory ITP, or severe ITP; or has persistent ITP, chronic ITP, or severe ITP and has an inadequate response to at least one prior anti-ITP treatment (such as first-line, second-line, and / or third-line anti-ITP treatment), a new relapse, and / or exacerbation.
[0135] The term "individual in need" in the context of treatment, as used in this article, refers to an individual who derives biological, medical, or quality-of-life benefits from the treatment.
[0136] As used in this article, “application” means provided, given, measured and / or prescribed by a medical practitioner or authorized agent, and / or administered, taken or consumed by a patient or the patient himself / herself.
[0137] The terms “effective amount,” “therapeutic effective amount,” or “pharmaceutical effective amount” as used herein are used interchangeably and include the amount of a compound, formulation, material, or composition sufficient to treat or suppress symptoms, signs, or other indicators of the condition to be treated. The effective amount for a particular patient may vary due to various factors, such as the condition being treated, the patient’s overall health status, the route and dosage of administration, and the severity of side effects. An effective amount can be the maximum dose or administration regimen that avoids significant side effects or toxicity. The effect will result in an improvement of at least 5%, such as at least 10%, further such as at least 20%, further such as at least 30%, further such as at least 40%, further such as at least 50%, further such as at least 60%, further such as at least 70%, further such as at least 80%, and even further such as at least 90%, where 100% is defined as a diagnostic parameter exhibited in a normal individual.
[0138] The term "AUC" tau,ss "" refers to the area under the blood drug concentration-time curve during the steady-state dosing interval.
[0139] The term "pharmaceutically acceptable" refers to compounds, materials, compositions, and / or dosage forms that are suitable for use in human and animal tissues without causing excessive toxicity, irritation, allergic reactions, or other problems or complications, and that are proportionate to a reasonable benefit / risk ratio.
[0140] "Pharmaceutically acceptable salts" can be formed, for example, as acid addition salts, preferably organic or inorganic acids. Suitable inorganic acids include halogenated acids, such as hydrochloric acid. Suitable organic acids are, for example, carboxylic acids or sulfonic acids, such as acetic acid, p-toluenesulfonic acid, malic acid, fumaric acid, or methanesulfonic acid, preferably acetic acid, more preferably monoacetic acid. For separation or purification purposes, pharmaceutically unacceptable salts, such as picrates or perchlorates, may also be used. For therapeutic uses, only pharmaceutically acceptable salts or free compounds (if applicable, in the form of pharmaceutical preparations) are used, and therefore these salts or free compounds are preferred. The term "free compound" as used herein should be understood to also refer to the corresponding salt, as appropriate.
[0141] The term "instructions for use" refers to the instructions that are typically included in the commercial packaging of a therapeutic product, which contain information about the indications, usage, dosage, administration, combination therapy, contraindications and / or warnings for such therapeutic products.
[0142] As used in this article, "combination" refers to the use of one treatment method in addition to another (such as drug therapy). Therefore, the term refers to the administration of another treatment method before, during, or after the administration of one treatment method to a patient.
[0143] As used herein, “one or more” or “at least one” means the presence of at least one specified element or parameter, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more. Similarly, “two or more” means 2, 3, 4, 5, 6, 7, 8, 9, 10 or more.
[0144] It is understood that the amount of compounds mentioned in this article (such as solepinib or its pharmaceutically acceptable salts) refers to the amount of the compound present in the form of a free base.
[0145] All numerical ranges in this document should be understood as disclosing every single value within the range and every subset of values within the range, regardless of whether they are otherwise specifically disclosed. For example, when referring to any numerical range, it should be considered as every single value within the range of exponential values, such as every single integer within the range of values. This disclosure includes all values within these ranges, all smaller ranges, and the upper or lower bounds of the ranges.
[0146] Solepinib (HMPL-523)
[0147] Sovleplenib (also known as HMPL-523) is a highly effective and selective small-molecule Syk inhibitor that inhibits the production of anti-platelet antibodies by B cells and inhibits macrophages from phagocytosing platelets coated with autoantibodies. Sovleplenib, or (S)-7-(4-(1-(methanesulfonyl)piperidin-4-yl)phenyl)-N-(morpholin-2-ylmethyl)pyrido[3,4-b]pyrazin-5-amine, has the following structure: .
[0148] In some embodiments, solepinib is provided and / or used in the form of a salt (e.g., a pharmaceutically acceptable salt). Pharmaceutically acceptable salts are known in the art. See, for example, SM Berge et al., J. Pharmaceutical Sciences, 1977, 66, 1-19.
[0149] In some embodiments, such as those described in patent application WO 2019 / 037737 A1, solepinib is provided and / or utilized in the form of a salt, such as an acetate, the entire contents of which are incorporated herein by reference.
[0150] Methods and uses
[0151] This disclosure provides a method for treating immune thrombocytopenic purpura (ITP) in individuals in need, the method comprising administering to the individual an effective amount of sorapinib or a pharmaceutically acceptable salt thereof.
[0152] In some implementations, ITP is primary ITP. In some implementations, ITP is newly diagnosed ITP. In some implementations, ITP is persistent ITP. In some implementations, an individual has persistent ITP for ≥3 months and less than 1 year. In some implementations, ITP is chronic ITP. In some implementations, an individual has chronic ITP for ≥1 year. In some implementations, an individual has chronic ITP for 1 to 2 years. In some implementations, an individual has chronic ITP for 1 to 3 years. In some implementations, an individual has chronic ITP for ≥3 years.
[0153] In some embodiments, the individual has received at least one prior anti-ITP treatment, optionally at least one prior line of treatment (e.g., one prior line of treatment, two prior lines of treatment, three prior lines of treatment, four prior lines of treatment, five prior lines of treatment, or more prior lines of treatment). In some embodiments, the individual has received at least one, two, three, four, five, six, seven, eight, or more prior anti-ITP treatments. In some embodiments, the individual has received at least two, three, four, five, six, seven, or more prior anti-ITP treatments. In some embodiments, the individual has received at least three, four, five, six, seven, or more prior anti-ITP treatments. In some embodiments, the individual has received at least four, five, six, or more prior anti-ITP treatments. In some embodiments, the individual has received four, five, or more prior anti-ITP treatments. In some embodiments, the individual has received at least four or more prior anti-ITP treatments. In some implementations, an individual has an inadequate or intolerable response to at least one prior anti-ITP treatment, or has relapsed after at least one prior anti-ITP treatment, for example, at least one prior line of anti-ITP treatment (e.g., one prior line of treatment, two prior lines of treatment, three prior lines of treatment, four prior lines of treatment, five prior lines of treatment, or more prior lines of treatment).
[0154] In some embodiments, at least one prior anti-ITP treatment includes splenectomy, anti-ITP drug therapy, or any combination of such treatments. In some embodiments, at least one prior anti-ITP treatment includes splenectomy. In some embodiments, at least one prior anti-ITP treatment includes anti-ITP drug therapy (e.g., standard anti-ITP drug therapy or non-standard anti-ITP drug therapy). In some embodiments, prior anti-ITP treatment includes one or more (e.g., 2, 3, 4, 5, or 6) treatments using corticosteroids, intravenous immunoglobulins, anti-D immunoglobulins, TPO therapy, TPO-RA therapy, anti-CD20 antibody therapy, immunosuppressants, vinca alkaloids, traditional Chinese medicine, platelet transfusions, danazol / stanozolol, cyclosporine, caffeic acid, IL-11, and / or other active agents. In some embodiments, at least one prior anti-ITP treatment includes treatment with corticosteroids (e.g., glucocorticoids selected from prednisone, prednisolone, dexamethasone, methylprednisolone, and betamethasone). In some embodiments, at least one prior anti-ITP treatment includes a platelet stimulant. In some embodiments, at least one prior anti-ITP treatment includes treatment with a TPO therapeutic agent (e.g., rhTPO). In some embodiments, at least one prior anti-ITP treatment includes treatment with a TPO-RA (e.g., at least one of eltrombopag, hetrombopag, avatrombopag, and romiplostim). In some embodiments, at least one prior anti-ITP treatment includes treatment with an anti-CD20 antibody (e.g., rituximab). In some embodiments, at least one prior anti-ITP treatment includes treatment with an immunosuppressant (e.g., at least one of cyclosporine A, azathioprine, and mycophenolate mofetil). In some embodiments, at least one prior anti-ITP treatment includes treatment with IVIG. In some embodiments, at least one prior anti-ITP treatment includes treatment with anti-D immunoglobulin. In some implementations, at least one prior anti-ITP treatment includes treatment with other active agents, such as alenzab, danazol and / or dapsone, or vinca alkaloids.
[0155] In some embodiments, at least one prior anti-ITP treatment includes TPO therapy and / or TPO-RA therapy. In some embodiments, at least one prior anti-ITP treatment includes either TPO therapy or TPO-RA therapy. In some embodiments, at least one prior anti-ITP treatment includes both TPO therapy and TPO-RA therapy. In some embodiments, at least one prior anti-ITP treatment includes only one drug of TPO / TPO-RA therapy. In some embodiments, at least one prior anti-ITP treatment includes at least two drugs of TPO / TPO-RA therapy (e.g., three, four, five, six, or more TPO / TPO-RA therapy drugs), for example, at least two (e.g., three, four, five, six, or more drugs) selected from recombinant human thrombopoietin, eltrombopag, hetrombopag, avatrombopag, and romiplostim.
[0156] In some implementations, the drug used for TPO treatment is recombinant human thrombopoietin. In some implementations, the drug used for TPO-RA treatment is selected from eltrombopag, hetrombopag, avatrombopag, and romiplostim.
[0157] In some embodiments, at least one prior anti-ITP treatment includes at least one first-line treatment, such as one or more drugs selected from glucocorticoids, including prednisone, prednisolone, dexamethasone, and betamethasone. In some embodiments, at least one prior anti-ITP treatment includes at least one second-line treatment, such as one or more drugs selected from rhTPO, romiplostim, eltrombopag, hetrombopag, or avatrombopag, rituximab, and splenectomy. In some embodiments, at least one prior anti-ITP treatment includes at least one third-line, fourth-line, or more lines of treatment.
[0158] In some embodiments, at least one prior anti-ITP treatment includes anti-CD20 antibody therapy. In some embodiments, the anti-CD20 antibody therapy is rituximab.
[0159] In some implementations, at least one prior anti-ITP treatment does not include a Syk inhibitor (including futtatinib).
[0160] In some implementations, the individual's pre-treatment ITP bleeding scale (IBLS) score (such as the WHO bleeding scale) is 0 or 1. In some implementations, the individual's pre-treatment platelet count is less than 30 × 10⁻⁶. 9 / L. In some implementations, the individual's platelet count before treatment is less than 15 × 10⁹ / L. 9 / L. In some implementations, the individual's platelet count before treatment is greater than 30 × 10⁹ / L. 9 / L and less than 30×10 9 / L. In some implementations, an individual's hemoglobin is ≥100 g / L and neutrophil count is greater than 1.5 × 10⁹ / L. 9 / L.
[0161] In some implementations, individuals do not respond to sorapinib during the first 12 weeks of treatment.
[0162] In some implementations, the individual is an adult. In some implementations, the individual is of Asian descent. In some implementations, the individual is of non-Asian descent. In some implementations, the individual is of Western descent.
[0163] Effectiveness and safety
[0164] The methods described herein can achieve sustained responses (relative to pre-treatment), including improved sustained response rate (DRR), improved overall response, including improved overall response rate (ORR), improved platelet count, including improved median platelet count, rapid onset or improved time to response (TTR), reduced incidence or severity of bleeding, including WHO bleeding scale reduction, reduced frequency of ≥ grade 3 bleeding, improved hemoglobin levels, long-term remission of ITP, improved health-related quality of life (HRQoL) (e.g., in terms of physical function, energy / fatigue, role limitations due to physical health, role limitations due to emotional problems, emotional health and / or general health), reduced use of emergency treatments, including emergency medications and / or reduced or interrupted baseline concomitant anti-ITP therapy, and safety and tolerability over longer periods, such as low risk of gastrointestinal toxicity.
[0165] Compared with existing technologies, the method presented herein has advantages, such as not only reducing the risk of excessive bleeding, but also inducing long-term remission of ITP, improving the health-related quality of life (HRQoL) of ITP patients as defined in this disclosure, while being safe and tolerable over a longer period of time.
[0166] In some implementations, an individual may be effectively treated even if their response to other therapies is inadequate, as administered according to the provided method. In some implementations, criteria for assessing effective treatment include sustained response rate (DRR), overall response rate (ORR), the proportion of patients receiving emergency treatment, the proportion of patients reducing or interrupting baseline concomitant treatment, and two consecutive platelet counts ≥30 × 10⁻⁶. 9 The proportion of patients whose platelet count doubled from baseline, the improvement in platelet count, time to response (TTR), WHO bleeding score, and / or health-related quality of life (HRQoL) are also considered. In some embodiments, the DRR of patients treated with the methods described herein is at least approximately 30% (e.g., at least 40%, at least 50%, at least 60%, at least 70%, or at least 80%). In some embodiments, the ORR of patients treated with the methods described herein is at least approximately 40% (e.g., at least approximately 50%, at least approximately 60%, at least approximately 70%, at least 80%, or at least 90%). In some embodiments, at least 30% (e.g., at least 40%, at least 50%, at least 60%, at least 70%, or at least 80%) of patients treated with the methods described herein achieve sustained efficacy. In some embodiments, less than approximately 35% of patients treated with the methods described herein received emergency treatment (e.g., less than approximately 30%, less than approximately 25%, less than approximately 20%, less than approximately 15%, less than approximately 10%, or less than approximately 5%). In some embodiments, at least 10% (e.g., at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, or at least 40%) of patients treated with the methods described herein achieved a significant reduction or discontinuation of baseline concomitant anti-ITP therapy. In some embodiments, at least 10% (e.g., at least 20%, at least 30%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%) of patients treated with the methods described herein had a platelet count ≥30 × 10⁻⁶ on two consecutive occasions. 9 / L, and doubled from baseline. In some implementations, on average, patients treated with the methods described herein had a median response time of less than about 4 weeks, about 3 weeks, about 2 weeks, about 1 week, about 7 days, about 6 days, about 5 days, about 4 days, about 3 days, about 2 days, or about 1 day. In some implementations, patients treated with the methods described herein had a mean WHO bleeding score (least square mean) of less than about 0.8, about 0.7, about 0.6, about 0.5, about 0.4, about 0.3, about 0.2, or about 0.1. In some implementations, patients treated with the methods described herein achieved, on average, improved health-related quality of life (HRQoL), for example, in terms of fatigue and / or physical functioning.
[0167] In some implementations, less than about 25% (e.g., less than about 20%, less than about 15%, less than about 10%, or less than about 5%) of patients treated with the methods described herein experience severe TEAEs.
[0168] In some implementations, less than about 2% (e.g., less than 1.9%, less than 1.8%, less than 1.7%, less than 1.6%, less than 1.5%, less than 1.4%, less than 1.3%, less than 1.2%, less than 1.1%, or less than 1.0%) of patients treated with the methods described herein experience treatment-related serious TEAEs.
[0169] In some embodiments, less than about 15% (e.g., less than 14%, less than 13%, less than 12%, less than 11%, less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, or less than 1%) of patients treated with the methods described herein experience hypertension. In some embodiments, less than about 5% (e.g., less than 4%, less than 3%, less than 2%, or less than 1%) of patients treated with the methods described herein experience grade 3 hypertension.
[0170] In some embodiments, less than about 15% (e.g., less than 14%, less than 13%, less than 12%, less than 11%, less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, or less than 1%) of patients treated with the methods described herein experience hypertension. In some embodiments, less than about 5% (e.g., less than 4%, less than 3%, less than 2%, or less than 1%) of patients treated with the methods described herein experience grade 3 hypertension.
[0171] In some embodiments, less than about 10% (e.g., less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, or less than 1%) of patients treated with the methods described herein experience gastrointestinal-related events (e.g., diarrhea, vomiting, nausea). In some embodiments, less than about 5% (e.g., less than 4%, less than 3%, less than 2%, or less than 1%) of patients treated with the methods described herein experience diarrhea. In some embodiments, less than about 5% (e.g., less than 4%, less than 3%, less than 2%, or less than 1%) of patients treated with the methods described herein experience vomiting. In some embodiments, less than about 5% (e.g., less than 4%, less than 3%, less than 2%, or less than 1%) of patients treated with the methods described herein experience nausea.
[0172] dose
[0173] In some implementations, the provided method includes administering a therapeutically effective amount of sorapinib or a pharmaceutically acceptable salt thereof to a patient in need.
[0174] It is understood that the amount of an active agent (such as solepinib or a pharmaceutically acceptable salt thereof) mentioned refers to the amount of the corresponding compound in its free base form. Therefore, if a compound is available and / or used in the form of, for example, a salt, the amount of any salt (or other form) mentioned represents the amount corresponding to the “free base equivalent” of that salt (or other form).
[0175] In some implementations, a therapeutically effective amount of sorapinib or a pharmaceutically acceptable salt thereof is sufficient in the patient to induce an AUC. tau,ss Values reaching approximately 600-5000 or approximately 600-4890 h × ng / mL, for example, approximately 600-800, approximately 1000-1300, approximately 1900-2200, or approximately 2900-3200 h × ng / mL; for example, approximately 600-700, approximately 1100-1200, approximately 2000-2100, or approximately 3000-3100 h × ng / mL; for example, approximately 640-680, approximately 1135-1175, approximately 2045-2185, or approximately 3045-3085 h × ng / mL; for example, approximately 650-670, approximately 1145-1165, approximately 2055-2175, or approximately 3055-3075 h × ng / mL (for example, approximately 661 h × ng / mL, approximately 1156 h × ng / mL). (approximately 2067 h × ng / mL, approximately 3065 h × ng / mL). In some embodiments, a therapeutically effective amount of sorapinib or a pharmaceutically acceptable salt thereof is sufficient to cause AUC... tau,ss = Approximately 1900-2200, approximately 2000-2100, approximately 2045-2185, approximately 2055-2175 or approximately 2067 h × ng / mL.
[0176] In some embodiments, the method provided includes administering about 100 mg to about 800 mg of sorapinib or a pharmaceutically acceptable salt thereof to a patient in need daily. In some embodiments, the method provided includes administering about 100, 200, 300, 400, 500, 600, 700, or 800 mg of sorapinib or a pharmaceutically acceptable salt thereof to a patient in need daily. The daily dose (i.e., the total daily dose) may be administered once daily (QD) or divided into several doses, such as twice daily (BID) or three times daily (TID).
[0177] In some embodiments, the provided method includes administering about 100 mg to about 800 mg of sorbipinib or a pharmaceutically acceptable salt thereof to a patient in need, once daily (QD). In some embodiments, the provided method includes administering about 100 mg to about 400 mg of sorbipinib or a pharmaceutically acceptable salt thereof to a patient in need, once daily (QD). In some embodiments, the provided method includes administering about 300 mg to about 500 mg of sorbipinib or a pharmaceutically acceptable salt thereof to a patient in need, once daily (QD). In some embodiments, the provided method includes administering about 100 mg of sorbipinib or a pharmaceutically acceptable salt thereof to a patient in need, once daily (QD). In some embodiments, the provided method includes administering about 200 mg of sorbipinib or a pharmaceutically acceptable salt thereof to a patient in need, once daily (QD). In some embodiments, the provided method includes administering about 300 mg of sorbipinib or a pharmaceutically acceptable salt thereof to a patient in need, once daily (QD). In some embodiments, the method provided includes administering about 400 mg of sorbipinib or a pharmaceutically acceptable salt thereof to a patient in need, once daily (QD). In some embodiments, the method provided includes administering about 500 mg of sorbipinib or a pharmaceutically acceptable salt thereof to a patient in need, once daily (QD). In some embodiments, the method provided includes administering about 600 mg of sorbipinib or a pharmaceutically acceptable salt thereof to a patient in need, once daily (QD). In some embodiments, the method provided includes administering about 700 mg of sorbipinib or a pharmaceutically acceptable salt thereof to a patient in need, once daily (QD). In some embodiments, the method provided includes administering about 800 mg of sorbipinib or a pharmaceutically acceptable salt thereof to a patient in need, once daily (QD).
[0178] In some embodiments, the method provided includes administering about 50 mg to about 400 mg of sorbipinib or a pharmaceutically acceptable salt thereof to a patient in need, twice daily (BID). In some embodiments, the method provided includes administering about 50 mg of sorbipinib or a pharmaceutically acceptable salt thereof to a patient in need, twice daily (BID). In some embodiments, the method provided includes administering about 100 mg of sorbipinib or a pharmaceutically acceptable salt thereof to a patient in need, twice daily (BID). In some embodiments, the method provided includes administering about 150 mg of sorbipinib or a pharmaceutically acceptable salt thereof to a patient in need, twice daily (BID). In some embodiments, the method provided includes administering about 200 mg of sorbipinib or a pharmaceutically acceptable salt thereof to a patient in need, twice daily (BID). In some embodiments, the method provided includes administering about 250 mg of sorbipinib or a pharmaceutically acceptable salt thereof to a patient in need, twice daily (BID). In some embodiments, the method provided includes administering about 300 mg of sorapinib or a pharmaceutically acceptable salt thereof to a patient in need, twice daily (BID). In some embodiments, the method provided includes administering about 350 mg of sorapinib or a pharmaceutically acceptable salt thereof to a patient in need, twice daily (BID). In some embodiments, the method provided includes administering about 400 mg of sorapinib or a pharmaceutically acceptable salt thereof to a patient in need, twice daily (BID).
[0179] In some embodiments, the dose of sorapinibub or a pharmaceutically acceptable salt thereof is reduced during the treatment described herein. In some embodiments, the dose of sorapinibub or a pharmaceutically acceptable salt thereof is reduced by about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, or about 95%. For example, the dose of sorapinibub or a pharmaceutically acceptable salt thereof at about 300 mg QD may be successively reduced to doses such as about 250 mg QD, about 200 mg QD, about 150 mg QD, or 100 mg QD; or the dose of sorapinibub or a pharmaceutically acceptable salt thereof at about 500 mg QD may be successively reduced to doses such as about 400 mg QD, about 300 mg QD, about 200 mg QD, or 100 mg QD.
[0180] In some embodiments, the methods of treating immune thrombocytopenic purpura (ITP) in individuals of need provided in this disclosure include administering a daily dose of about 300 to 500 mg (e.g., about 300 mg, about 400 mg, about 500 mg) or sufficient to reduce AUC. tau,ss The value reaches approximately 2055-2175 h × ng / mL (e.g., 2067 h × ng / mL). Sorapinib or a pharmaceutically acceptable salt thereof is administered to an individual at a dose of ng / mL, wherein the individual is a non-Asian population (e.g., Western, American, European, Caucasian, Oceanian (Australian-like) and / or African), and wherein the individual responds to and / or tolerates the treatment, for example, after treatment with sorapinib or a pharmaceutically acceptable salt thereof, the individual has a sustained response (including improved sustained response rate), improved overall response (including improved overall response rate), improved platelet count, rapid onset or improved response time, reduced incidence or severity of bleeding, including a decrease in WHO Bleeding Scale score, a decrease in the frequency of ≥ grade 3 bleeding, improved hemoglobin levels, long-term remission of ITP, improved health-related quality of life (HRQoL) and / or reduced use of emergency treatment and / or reduced or interrupted baseline concomitant anti-ITP treatment, and / or is safe and tolerable over time, with an optional low risk of gastrointestinal toxicity.
[0181] In some embodiments, solepinib is administered orally. In some embodiments, solepinib is administered with or without food.
[0182] Combination therapy
[0183] In some implementations, individuals may optionally receive concomitant anti-ITP treatment. In some implementations, the method provided includes administering a therapeutically effective amount of sorapinib or a pharmaceutically acceptable salt thereof to a patient in need, in combination with concomitant anti-ITP treatment (such as concomitant medication or emergency treatment).
[0184] In some implementations, concomitant anti-ITP therapy is a combination of no more than one medication selected from corticosteroids, danazol, and immunosuppressants. In some implementations, the corticosteroid is a glucocorticoid. In some implementations, the immunosuppressant is azathioprine, cyclosporine A, and / or mycophenolate mofetil. In some implementations, concomitant anti-ITP therapy is a TPO-RA treatment. In some implementations, concomitant anti-ITP therapy is an emergency treatment (such as platelet transfusion, intravenous immunoglobulin, or high-dose glucocorticoid pulse therapy).
[0185] In some embodiments, prior to the treatment provided herein, concomitant medications have been administered at a stable dose (e.g., a glucocorticoid dose equivalent to prednisone ≤20 mg / day for at least 2 weeks, or danazol or azathioprine at a stable dose for at least 3 months). In some embodiments, during the treatment provided herein, the dose of the concomitant medication is reduced by at least about 10%, at least about 20%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, or about 95%. In some embodiments, concomitant medications are discontinued during the treatment provided herein.
[0186] Unit dosage form
[0187] In some implementations, the provided therapy is administered in one or more unit dosage forms. As used herein, a “unit dosage form” refers to a physically discrete unit of an active agent (such as a therapeutic agent) for use by a patient. Typically, each unit contains a predetermined amount of active agent. It is understood that the total amount of therapeutic composition or active agent administered to a patient may involve the administration of multiple unit dosage forms.
[0188] In some embodiments, sorapinib is administered to the patient in a unit dosage form. In some embodiments, the unit dosage form is a capsule or tablet. In some embodiments, the unit dosage form comprises about 100 mg of sorapinib or a pharmaceutically acceptable salt thereof. In some embodiments, the unit dosage form comprises about 150 mg of sorapinib or a pharmaceutically acceptable salt thereof.
[0189] Pharmaceutically acceptable compositions
[0190] In some embodiments, the provided method includes administering one or more compositions comprising solepinib or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, excipient, or medium. In some embodiments, the provided compositions are formulated for oral administration.
[0191] The term "pharmaceutically acceptable carrier, excipient, or medium" refers to a non-toxic carrier, excipient, or medium that does not impair the pharmacological activity of the compound it is formulated with. Pharmaceutically acceptable carriers, excipients, or media that can be used in the compositions of this disclosure include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins (such as human serum albumin), buffering substances (such as phosphates, glycine, sorbic acid, potassium sorbate), mixtures of partial glycerides of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, dipotassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulose, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-polyoxypropylene block polymers, polyethylene glycol, and lanolin.
[0192] The composition can be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, or orally, vaginally, or through an implanted reservoir. As used herein, the term "parenterally" includes subcutaneous, intravenous, intramuscular, intra-articular, intrasynovial, intrasternal, intrathecal, intrahepatic, intralesional, and intracranial injection or infusion techniques. Preferably, the composition is administered orally.
[0193] Pharmaceutically acceptable compositions used in the provided methods can be administered orally in any oral dosage form, including but not limited to capsules, tablets, aqueous suspensions, or solutions. For oral tablets, common carriers include lactose and corn starch. Lubricants, such as magnesium stearate, are often added. When administered orally in capsule form, useful diluents include lactose and dried corn starch. When an oral aqueous suspension is required, the active ingredient is combined with an emulsifier and a suspending agent. Sweeteners, flavoring agents, or coloring agents may also be added if desired.
[0194] Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs.
[0195] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and / or a) fillers or extenders such as starch, lactose, sucrose, glucose, mannitol, and silicate; b) binders such as carboxymethyl cellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose, and gum arabic; c) humectants such as glycerin; d) disintegrants such as agar, calcium carbonate, potato or cassava starch, alginate, certain silicates, and sodium carbonate; e) solution blockers such as paraffin; f) absorption enhancers such as quaternary ammonium compounds; g) wetting agents such as cetyl alcohol and glyceryl monostearate; h) absorbents such as kaolin and bentonite; and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets, and pills, the dosage form may also contain buffers.
[0196] Similar solid compositions can also be used as fillers in soft and hard-filled gelatin capsules, which use excipients such as lactose or sugars from milk and high molecular weight polyethylene glycol. Solid dosage forms of tablets, sugar-coated pills, capsules, pellets, and granules can be prepared using coatings and shells, such as enteric coatings and other coatings known in the field of pharmaceutical formulation. They may optionally contain light-blocking agents and may also be compositions in which they optionally release the active ingredient in a delayed manner, either alone or preferably in a portion of the intestine. Examples of encapsulation compositions that can be used include polymers and waxes.
[0197] The compound can also exist in the form of microcapsules together with one or more excipients as described above.
[0198] Various embodiments have been described for illustrative purposes, but are not intended to be exhaustive or limited to the disclosed embodiments. Many modifications and variations thereto will be apparent to those skilled in the art without departing from the scope and spirit of the described embodiments.
[0199] To the extent permitted by law, all patents, patent applications, publications, and other references cited or mentioned herein are incorporated herein in their entirety. The discussion of these references is intended only to summarize the claims made therein. It does not imply endorsement that any such patent, patent application, publication, or reference, or any part thereof, is relevant material or prior art. The right to challenge the accuracy and relevance of these patents, patent applications, publications, and other references as relevant material or prior art is specifically reserved.
[0200] Example
[0201] This disclosure is further illustrated by the following examples, which should not be construed as limiting the scope or spirit of this disclosure to the specific procedures described herein. It should be understood that the examples are provided to illustrate certain implementations and not to limit the scope of this disclosure. It should also be understood that various other implementations, modifications, and equivalents may be drawn upon by those skilled in the art without departing from the spirit of this disclosure and / or the scope of the appended claims.
[0202] Example 1: Sorapinib in adult patients with primary immune thrombocytopenic purpura in China: A randomized, double-blind, placebo-controlled phase 1b / 2 study
[0203] Overall Design of the Study
[0204] This is a randomized, double-blind, placebo-controlled phase 1b clinical trial in subjects with persistent ITP / chronic ITP / refractory ITP lasting >6 months. Subjects were enrolled in this study only after signing informed consent and passing a screening process.
[0205] The primary objective of this study is to evaluate the safety and tolerability of different proposed doses of HMPL-523 and to determine the recommended dose of HMPL-523 in a Phase II clinical trial for primary immune thrombocytopenic purpura (ITP) in adults. Furthermore, the preliminary efficacy and pharmacokinetic (PK) characteristics of HMPL-523 in treating ITP will be further assessed. Blood samples will be collected from all subjects for PK analysis.
[0206] The estimated enrollment is 24-60 participants, but the final sample size depends on the number of study cohorts and the number of participants enrolled in each cohort. Based on a comprehensive analysis of efficacy, safety, and pharmacokinetic (PK) data, the actual sample size may be lower than planned.
[0207] Three dosage groups were initially set: 100 mg, 200 mg, and 300 mg (if no safety incidents occur during the dose escalation, the safety review committee may include another dosage group (100 mg increments)).
[0208] Eight participants will be initially enrolled in each dose group, drawn into the HMPL-523 and placebo groups at a 3:1 ratio, and will receive either HMPL-523 or placebo for eight weeks. After completing the eight-week blinded study treatment, all participants (including those in the HMPL-523 and placebo groups) will be eligible for 16 weeks of open-label HMPL-523 treatment at their current dose levels, subject to investigator evaluation.
[0209] Starting with the low-dose group, new subjects can only be re-enrolled to enter the next dose gradient study after all subjects in the previous dose group have completed 4 weeks of treatment and the safety and tolerability have been confirmed.
[0210] Subjects should be administered the medication at relatively fixed times each day. The actual administration times on the day before, the day of, and the day after PK sampling must be accurately recorded.
[0211] The Drug Safety Monitoring Committee (SRC) will summarize the safety data 28 days after the 8th subject in each dose group, and discuss whether to escalate to the next dose group, add a new dose group, increase the sample size in one or more dose groups, terminate dose escalation, terminate the current cohort study, or terminate the entire study. If necessary, ad hoc SRC meetings may also be convened during a dose study to decide whether to continue the study or adjust the study dose. The composition and responsibilities of the SRC are detailed in Section 3.4.
[0212] Dose escalation will be considered to be terminated if any of the following conditions occur: The planned maximum dose has been reached; SRC decides to terminate dose escalation; The sponsor has decided to terminate the dose escalation. From the first dose to 28 days after administration: o One or more SAEs related to HMPL-523 occurred (if necessary, the SRC requested individual unblinding of the SAEs to exclude placebo group subjects), excluding SAEs resulting from emergency ITP treatment; or o More than half of the subjects experienced a grade ≥2 drug-related adverse event according to CTCAE version 5.0 (unblinded).
[0213] During the study, the SRC will also select one or more dose groups to expand the sample size based on available safety and preliminary efficacy data, to further evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetic characteristics of HMPL-523 at these dose levels. The expanded sample size (i.e., patients enrolled after the 8th patient in each dose group [excluding]) will have the same randomization method and treatment procedure as the first 8 patients in that dose group.
[0214] The total number of cases enrolled in each dose group is tentatively set at 8-20, and may be adjusted based on the obtained safety, efficacy and pharmacokinetic data.
[0215] Based on comprehensive safety, tolerability, PK data, and preliminary efficacy, the SRC determined an appropriate dose as the recommended dose (RP2D) for a subsequent Phase 2 study of HMPL-523 in the treatment of primary immune thrombocytopenic purpura in adults.
[0216] Security assessment
[0217] All adverse events (SAEs) occurring within 28 days of the first administration of the study drug or before the initiation of new anti-ITP therapy (whichever occurs first) will be collected from the participants. SAEs occurring between informed consent and 28 days after the last administration of the study drug, and SAEs related to study drug treatment occurring after 28 days after the last administration of the study drug or after the initiation of new anti-ITP therapy (whichever occurs first), will be classified according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.
[0218] efficacy assessment
[0219] During the study, planned visits were conducted weekly for the first 8 weeks (inclusive) and every 2 weeks thereafter to assess the subjects' disease-related symptoms / signs and platelet levels.
[0220] Pharmacokinetic assessment
[0221] Blood samples will be collected from all subjects for pharmacokinetic (PK) analysis.
[0222] Randomization methods and procedures
[0223] Subject enrollment requires sponsor confirmation before randomization, and randomization can proceed if a subject meets all screening criteria. Researchers register for screening by logging into the Interactive Web Response System (IWRS) online and completing the IWRS worksheet. Eligible subjects will be randomly assigned to either the HMPL-523 group or the placebo group according to a predetermined ratio and in a blinded manner. Each subject's randomization number will be provided to the researchers via the IWRS.
[0224] After being randomly assigned to groups, the treatment study began on the same day.
[0225] Participants who terminate the study after signing the ICF but before the start of randomization will be considered "screening failures." Previously unsuccessful participants may be allowed a second screening, but a new participant number must be provided and a randomization number reassigned through the IWRS. This situation requires review by the sponsor on a case-by-case basis.
[0226] Research Objective
[0227] Main purpose: To evaluate the safety and tolerability of HMPL-523 in treating adult patients with primary immune thrombocytopenic purpura (ITP).
[0228] Determine the recommended dose of HMPL-523 in subsequent clinical studies in adults with primary ITP (Phase 2 recommended dose [RP2D]).
[0229] Secondary objective: To evaluate the preliminary efficacy of different doses of HMPL-523 in treating primary ITP in adults.
[0230] To investigate the pharmacokinetic (PK) characteristics of HMPL-523 and its major metabolites in adult patients with primary ITP.
[0231] Research Evaluation
[0232] Safety assessment
[0233] Adverse events should be identified and graded according to NCI CTCAE 5.0, and safety and tolerability should be comprehensively evaluated based on the incidence, severity, and outcome of adverse events. Investigators should promptly implement appropriate treatment measures for any adverse events and determine the relationship between the adverse event or SAE and the investigational drug. If a serious safety issue occurs in the study, the sponsor and investigator should jointly decide whether to terminate the study; the sponsor may also proactively request termination of the clinical study depending on the circumstances.
[0234] The safety of the investigational drug will be evaluated through adverse events / SAEs, vital signs, physical examination, laboratory tests, and 12-ECG.
[0235] Pharmacokinetic evaluation
[0236] The following indicators will be used to evaluate the PK characteristics of plasma HMPL-523 and its main metabolites: steady-state peak concentration (C). max,ss ), steady-state valley concentration ( Cmin,ss Steady-state peak time (T) max,ss Elimination half-life (t) 1 / 2 The area under the plasma concentration-time curve (AUC) during the steady-state dosing interval tau,ss ), steady-state apparent clearance rate (CL / Fss), steady-state apparent distribution volume (Vd / Fss), steady-state average residence time (MRTss), etc.
[0237] Therapeutic effect evaluation
[0238] The efficacy was evaluated using platelet count and the WHO bleeding score.
[0239] Primary therapeutic endpoint:
[0240] During the first 8 weeks of medication (including week 8), two consecutive visits were conducted, and the platelet count was ≥30×10⁻⁶. 9 The percentage of subjects whose blood alcohol level was / L and doubled from baseline (without receiving emergency treatment during the period).
[0241] Secondary therapeutic endpoint:
[0242] 0-8 weeks
[0243] 1. Platelet count ≥50×10⁸ at weeks 2, 3, 4, 5, 6, 7, and 8 after drug administration. 9 Percentage of subjects with a weight of / L; 2. Platelet count ≥30×10⁸ at weeks 2, 3, 4, 5, 6, 7, and 8 after drug administration. 9 / L, and at least 20×10 more than the baseline. 9 Percentage of subjects with a weight of / L; 3. Platelet count ≥30×10⁸ at weeks 2, 3, 4, 5, 6, 7, and 8 after drug administration. 9 / L, and the percentage of subjects whose levels have at least doubled from baseline; 4. Platelet count ≥50×10⁻⁶ at least once. 9 Percentage of subjects with a weight of / L; 5. Platelet count ≥30 × 10⁻⁶ at least once. 9 / L and an increase of ≥20×10 from baseline 9 Percentage of subjects with a weight of / L; 6. From the start of drug administration until the first platelet count ≥50×10⁻⁶. 9 / L requires time; 7. From the start of drug administration until the first platelet count ≥30×10⁻⁶. 9 / L requires time; 8. From the start of administration until the first platelet count increases by ≥20 × 10⁻⁶ from baseline. 9 / L requires time; 9. Platelet count at each visit time point; 10. Percentage of subjects who received emergency treatment; 11. Bleeding scores at each visit time point according to the WHO bleeding scoring criteria; 12. The platelet count of the subjects was ≥30×10⁻⁶. 9 / L and ≥50×10 9 The longest duration of / L; 13. The platelet count of the subjects was ≥30×10⁻⁶. 9 / L and ≥50×10 9 / L cumulative duration; 14. Platelet count ≥30×10⁻⁶ after 8 weeks of treatment (visit on day 57). 9 / L and an increase of ≥20×10 from baseline 9 The percentage of subjects who did not receive emergency treatment during the treatment period; 15. At least one platelet count ≥30×10 9The percentage of subjects whose blood alcohol content was / L and doubled from baseline (without receiving emergency treatment during treatment).
[0244] 0-24 weeks
[0245] 1. Platelet count ≥50×10⁶ in at least 4 out of the last 6 scheduled visits (weeks 14-24). 9 Percentage of subjects with a weight of / L; 2. Platelet count ≥50×10⁻⁶ at week 24 9 Percentage of subjects with a weight of / L; 3. Baseline platelet count <15×10 9 / L, and platelets ≥30×10 at 24 weeks 9 / L and an increase of ≥20×10 from baseline 9 / L of patients; 4. Platelet count ≥30×10 9 The longest duration that is / L and doubles the baseline level; 5. Platelet count ≥30×10 9 / L and the cumulative duration that is double the baseline level; 6.8-24 weeks of age, at least one platelet count ≥50×10⁶. 9 Percentage of subjects with a weight of / L; 7. Platelet count ≥ 50 × 10⁻⁶ 9 The longest duration of / L; 8. Platelet count ≥ 50 × 10⁻⁶ 9 / L cumulative duration; 9. Platelet count at each visit time point; 10. Percentage of subjects who received emergency treatment; 11. Incidence of bleeding-related events.
[0246] Target audience
[0247] The enrolled population consisted of individuals with persistent ITP / chronic ITP / refractory ITP who had thrombocytopenia for more than 6 months.
[0248] Selection criteria
[0249] To be eligible for selection, participants must meet all of the following criteria:
[0250] 1. Voluntary signing of ICF; 2. Men or women aged 18 to 75; 3. Physical condition score (ECOG score): 0-1 point; 4. The patient had been diagnosed with ITP prior to randomization and had had thrombocytopenia for more than 6 months; 5. At least for those who have failed first-line ITP treatment or have relapsed after treatment; or who have a poor response to splenectomy or have relapsed after surgery; 6. The condition is relatively stable, with a WHO bleeding grade of 0-1, and researchers have determined that no emergency treatment is expected within 2 weeks; 7. Laboratory tests meet the following criteria (no treatment for this indicator has been received within one week prior to blood collection): During the screening period, two platelet counts (with an interval of at least 24 hours between the two tests) must both be less than 30 × 10⁻⁶. 9 / L; Hemoglobin ≥ 90 g / L (if iron deficiency anemia is confirmed, hemoglobin > 80 g / L is acceptable for enrollment), white blood cell count > 2.5 × 10⁻⁶. 9 / L, neutrophils >1.8×10 9 / L; Serum creatinine concentration ≤ 1.5 times the upper limit of normal reference range (ULN), and creatinine clearance ≥ 50 mL / min; Total bilirubin (TBIL), ALT, and AST ≤ 1.5 × ULN; Serum amylase or lipase levels did not exceed the ULN; The International Normalized Ratio (INR) and Activated Partial Thromboplastin Time (APTT) values were within 20% of the normal range.
[0251] 8. Male or female participants of fertility must agree to use an effective method of contraception, such as a double barrier method, condom, oral or injectable contraceptive, intrauterine device, etc., during the study period and for 90 days after the last study dose. This condition does not apply to postmenopausal women (>50 years of age and last menstruation for more than 1 year) and women who have undergone surgical sterilization.
[0252] 9. This study allows participants to receive stable-dose anti-ITP medication in combination with other treatments; detailed requirements are as follows: Corticosteroids: A stable dose (equivalent to prednisone ≤20 mg / day) has been maintained for at least 2 weeks prior to randomization, or the drug has been discontinued for at least 2 weeks prior to randomization; Danazol or azathioprine: A stable dose has been maintained for at least 3 months prior to randomization, or the drug has been discontinued 4 weeks prior to randomization; Exclusion criteria The primary exclusion criteria were secondary thrombocytopenia, a history of severe cardiovascular disease, uncontrolled hypertension, and diseases requiring long-term use of medications that affect platelet function. Based on safety considerations from earlier studies, pregnant and lactating patients were excluded.
[0253] Research on treatment
[0254] Research drugs
[0255] HMPL-523 tablets or HMPL-523 placebo tablets are light yellow tablets available in strengths of 25 mg / tablet, 100 mg / tablet, and 150 mg / tablet; packaged in white high-density polyethylene bottles containing 30 tablets per bottle, and stored below 25°C.
[0256] Administration method
[0257] Subjects must be given medication at the research center on each visit day.
[0258] Take HMPL-523 tablets or HMPL-523 placebo tablets with 250 mL of warm water within 30 minutes after a meal.
[0259] 100 mg dose group: 100 mg / dose, QD × 8 weeks 200 mg dose group: 200 mg / dose, QD × 8 weeks 300 mg dose group: 300 mg / dose, QD × 8 weeks Other: SRC may adjust some of the above-mentioned dosing regimens or add new dosing regimens. If necessary (if the subject experiences intolerance, such as abdominal pain), the dosing may be changed to twice daily while maintaining the total daily dose.
[0260] On each visit day, the subject must be given medication at the research center and must take it with 250 mL of warm water.
[0261] After completing 8 weeks of blinded treatment, all patients were assessed by the investigators and deemed eligible to receive 16 weeks of open-label treatment with the same dose level of HMPL-523.
[0262] Administration time: Patients should take this medication at a relatively fixed time each day. The actual administration time should be accurately recorded the day before, the day before, and the day after PK sampling.
[0263] Dosage adjustment
[0264] Study drug dosage adjustment
[0265] Eight subjects in each dose group were not required to undergo dose adjustments during the first 28 days of treatment; otherwise, dose adjustments were recommended according to the following rules. HMPL-523 treatment may be discontinued if a subject experiences any of the following drug-related adverse events (CTCAE V5.0). If the adverse event returns to baseline or is ≤ Grade 1 within 14 days of discontinuation, administration can be resumed at a lower dose level; otherwise, permanent discontinuation is necessary. The following dose reduction principles are for reference: it is recommended to reduce the dose sequentially at 250 mg, 200 mg, 150 mg, and 100 mg dose levels (reducing sequentially from the current dose level as the highest point), or consider dividing the total daily dose into two doses while maintaining the same total daily dose.
[0266] ≥G3 ALT elevation, AST elevation or TBIL elevation ≥G3 lung infection ≥G3 neutropenia Symptomatic interstitial lung disease Pancreatitis requiring treatment intervention Kidney dysfunction requiring treatment intervention Other significant adverse events as determined by the researchers.
[0267] During treatment, if platelet count >250×10 9 / L and < 400×10 9 If platelet count reaches 14 days, the study drug can be reduced by one dose level. If the protocol allows for concomitant anti-ITP therapy, the reduction of the dose of other anti-ITP therapy should be given priority; if platelet count ≥400×10⁶ / L, the study drug dose can be reduced by one level. 9 If the platelet count is <400×10⁹ / L, research drug treatment can be suspended until the platelet count is <400×10⁹ / L. 9 / L, then administer at a lower dose level.
[0268] Adjustment of anti-ITP treatment dosage
[0269] The following criteria can be used as a reference for dose adjustments in combination with anti-ITP therapy:
[0270] During or after treatment with stable doses of concomitant anti-ITP therapy, doses cannot be increased to higher levels; any dose increase is considered an emergency treatment.
[0271] Combined medication
[0272] All drug treatments and meaningful non-drug treatments (including health supplements) must be recorded from the 28 days prior to randomization to the 28 days following the end of treatment.
[0273] Permitted concomitant medication
[0274] Participants cannot receive other concurrent anti-ITP treatments throughout the study, except in the following circumstances: Prior to randomization, the patient was receiving a stable dose of one of the following medications for ITP: glucocorticoids, azathioprine, or danazol. Emergency treatment (including: platelet transfusion, intravenous immunoglobulin, high-dose glucocorticoid pulse therapy) Subjects who received emergency treatment were considered unresponsive during the treatment period, and this continued until the emergency treatment ended and their platelet count was <30×10⁻⁶. 9 / L. Adding other new anti-ITP therapies or increasing the dose or frequency of concomitant anti-ITP therapies permitted by the protocol is considered emergency treatment.
[0275] Sample size calculation and statistical analysis
[0276] Calculation of sample size
[0277] Three dosage groups (cohorts) were initially planned: 100 mg, 200 mg, and 300 mg. Each dosage group consisted of 8–20 subjects (6–15 in the HMPL-523 group and 2–5 in the placebo group). The final sample size depended on the number of study cohorts and the number of subjects enrolled in each cohort. For adverse events with an incidence of 10%, 5%, or 1%, the probabilities of observing at least one adverse event in a given cohort of at least 6 subjects taking HMPL-523 were 46.9%, 26.5%, and 5.8%, respectively, and the probabilities of observing at least one adverse event in a given cohort of at least 15 subjects taking HMPL-523 were 79.4%, 53.7%, and 14.0%, respectively.
[0278] Statistical analysis
[0279] Generally, continuous variables (such as age) will be statistically described using the number of observations, mean, median, standard deviation, minimum, and maximum; categorical variables will be statistically described using the frequency and percentage of each category. If the data allows, the event occurrence time variable will be calculated using the Kaplan-Meier method to determine the quartiles, median, and their 95% confidence intervals.
[0280] Statistical Analysis Set
[0281] This study includes the following analysis set:
[0282] Intention-to-treat (ITT) Set: This set includes all randomized participants, grouped according to their randomization group. It was used to analyze all efficacy endpoints.
[0283] Safety Set (SS): This set includes subjects who received at least one treatment with the study drug. Subjects are grouped according to the actual treatment received. This set is used for the analysis of all safety data.
[0284] Pharmacokinetic set (PK set): This set includes subjects who have received at least one treatment with the study drug and whose PK blood samples have been collected and analyzed. This set is used for the analysis of blood drug concentrations and pharmacokinetic parameters.
[0285] Analytical methods
[0286] Security Analysis
[0287] All analyses of the security endpoint are based on the security set (SS).
[0288] The severity of adverse events (AEs) is graded according to NCI CTCAE version 5.0 (level 1 to 5).
[0289] The incidence of TEAEs will be summarized according to system organ classification (SOC) and preferred term (PT), and further summarized at the SOC and PT levels based on the severity of the TEAEs and their closest relationship with the investigational drug.
[0290] Therapeutic effect analysis
[0291] All efficacy endpoints were analyzed based on the intention-to-treat (ITT) set.
[0292] The primary efficacy endpoint of this study was a platelet count ≥30 × 10⁻⁶ during two consecutive visits within the first 8 weeks of treatment (including week 8). 9 The percentage of subjects whose blood alcohol level ( / L) doubled from baseline (without receiving emergency treatment during the period). If a subject received emergency treatment due to worsening of their condition during treatment, the treatment was considered ineffective.
[0293] For the primary efficacy endpoint, the exact 95% confidence intervals for each group rate were calculated using the Clopper-Pearson method, and the 95% confidence intervals for the difference in response rates between the placebo group and the different doses of HMPL-523 groups were calculated using the normal approximation method. The exact probability method was used to test between groups. To explore the influence of prognostic factors that may affect efficacy, multivariate logistic regression analysis was used, with the model including treatment (a categorical variable) and potential prognostic factors. The odds ratio (OR) of treatment relative to placebo and its 95% confidence interval, as well as the corresponding p-value, were calculated using the model.
[0294] The analysis of other secondary efficacy endpoints in the binary classification used the same statistical analysis methods as the primary efficacy endpoints.
[0295] For event occurrence time variables (e.g., from the start of drug administration until the first platelet count ≥50×10⁻⁶), 9 The time required for the platelet count to remain ≥50 × 10⁹ / L is required, and the subject's platelet count must be consistently ≥50 × 10⁹ / L. 9 The longest duration of / L was used to estimate the quartiles, median, and their 95% confidence intervals using the Kaplan-Meier method. For comparisons between groups, the log-rank test can be considered.
[0296] Pharmacokinetic analysis
[0297] All pharmacokinetic parameters will be statistically described based on the pharmacokinetic analysis set, grouped by dose. Pharmacokinetic parameters will be calculated using a non-compartmental model with Phoenix WinNonlin software. A summary of pharmacokinetic parameters will report the total number of cases, number of missing cases, mean, standard deviation, median, minimum, maximum, geometric mean, and coefficient of variation of the geometric mean. If necessary, exponential and ANOVA models will be considered to assess the existence of dose proportionality.
[0298] Mid-term analysis
[0299] To more precisely explore the optimal dose of HMPL-523 for ITP, a third-party statistical team will unblind the subjects in each dose cohort after the first 8 subjects complete 8 weeks of treatment, providing the sponsor with interim summary data on safety and efficacy for that cohort. The SRC will use this interim summary data to further determine whether to explore new dose groups, new dosing regimens, or increase the enrollment in one or more dose groups. Additional unblinding analyses may be added during the study execution, depending on the data observed. These additional unblinding analyses will be presented in the statistical analysis plan.
[0300] Research Results
[0301] Between May 30, 2019, and April 22, 2021, 62 patients were eligible for evaluation and 45 (73%) were randomized (33 in the dose escalation phase and 12 in the dose expansion phase). Interim analysis showed no protocol-mandated safety events requiring termination of dose escalation. Based on 28 days of safety data and interim analysis results, the Safety Review Board recommended that the study include 400 mg of sorapinib once daily, thus expanding the patient cohort. During the 8-week double-blind period, all enrolled patients received at least one dose of the investigational drug (placebo [n=11] and sorapinib 100 mg [n=6], 200 mg [n=6], 300 mg [n=16; 6 patients from the dose escalation phase and 10 patients from the dose expansion phase], and 400 mg [n=6]). No emergency unblinding occurred during the study.
[0302] Overall, HMPL-523 was considered safe and well-tolerated in this group of ITP subjects. MTD was not reached. During the 28-day safety assessment period, two ≥ grade 2 treatment-related adverse events (TRAEs) occurred in the HMPL-523 group (one hypertriglyceridemia event at the 100 mg QD dose level and one anemia event at the 200 mg QD dose level). The most frequently reported HMPL-523 TRAEs during the 0–8 week treatment period were elevations in aspartate aminotransferase (29%), alanine aminotransferase (ALT; 27%), and serum lactate dehydrogenase (22%). The safety profile of HMPL-523 was generally similar across all dose levels. No drug-related serious adverse events (SAEs) or drug-related treatment discontinuations were reported in this study. Notably, no drug-related adverse events (AEs) of increased platelet counts or thromboembolic events were reported.
[0303] Efficacy is measured by ORR (defined as a platelet count of ≥50 × 10⁻⁶ at least once during treatment). 9 The percentage of subjects who did not receive emergency treatment ( / L) and the sustained response rate (DRR; defined as a platelet count of ≥50 × 10⁹ / L in at least four out of six bi-weekly follow-ups during the treatment period, between week 14 and week 24 (inclusive)). 9The percentage of subjects receiving HMPL-523 (N = 34) was assessed. As shown in Table 1, during the 8-week double-blind treatment period, 3 (50.0%), 2 (33.3%), 11 (68.8%), and 2 (33.3%) subjects receiving HMPL-523 at QD dose levels of 100 mg (N = 6), 200 mg (N = 6), 300 mg (N = 16), and 400 mg (N = 6), respectively, achieved an overall response. Five (31.3%) subjects receiving the 300 mg QD dose achieved a sustained response, but none of the subjects receiving the 200 mg and 400 mg QD doses achieved a sustained response (this assessment was not performed on any subjects receiving the 100 mg dose). Subjects responded rapidly to treatment, with 75% of subjects achieving their first response (defined as a platelet count ≥30 × 10⁻⁶) within 1.1 weeks of starting HMPL 523 at the 300 mg QD dose. 9 / L). No subject had a platelet count exceeding 300 × 10⁹ / L. 9 / L indicates a low risk of thromboembolism.
[0304] Based on safety and overall efficacy, the 300 mg QD was determined to be the RP2D. In all subjects, including the double-blind and open-label periods (N = 20), the ORR in the 300 mg QD dosing group was 80% (16 subjects). The DRR for this subject population was 40% (8 subjects).
[0305] Table 1: Efficacy of different dose levels in treating subjects
[0306] Abbreviations: NA = Not applicable; or ORR = Overall response rate; PLT = Platelets
[0307] a This table only lists the ORR for the double-blind period from 0 to 8 weeks.
[0308] b 100-mg dose, open label period N = 0.
[0309] c 200-mg dose, open label period N = 4.
[0310] In this study, pharmacokinetic characterization of HMPL-523 was performed on day 15 in Chinese ITP subjects following multiple 100-400 mg QD doses in the dose escalation phase and multiple 300 mg QD doses in the dose extension phase. All subjects were instructed to take HMPL-523 approximately 30 minutes after a meal in this study.
[0311] Following multiple doses of HMPL-523 (100-400 mg QD), the median t-value of HMPL-523 was... max The value is 4.0 hours after administration. Within a dose range of 100 to 400 mg QD, the systemic exposure (maximum steady-state plasma drug concentration [C]) is... max,ss ] and AUC tau,ss It increases in a dose-proportional manner. Following administration of RP2D 300 mg QD, the geometric mean C of HMPL-523... max,ss Minimum steady-state plasma drug concentration (C min,ss ) and AUC tau,ss The concentrations were 163 ng / mL, 41.3 ng / mL, and 2070 h× ng / mL, respectively. CL on day 15... ss / F ranges from 130 to 173 liters per hour (see Table 2)
[0312] Table 2 Pharmacokinetic parameters of HMPL-523
[0313] Example 2: Efficacy and safety of solepinib in Chinese adult patients with primary immune thrombocytopenic purpura (ITP) (ESLIM-01): A randomized, double-blind, placebo-controlled phase III study.
[0314] Overall research design
[0315] This is a randomized, double-blind, placebo-controlled phase III clinical trial in adult patients with persistent or chronic ITP. The aim is to evaluate the efficacy and safety of HMPL-523 compared to placebo in ITP patients who have not responded adequately to at least one prior standard ITP treatment.
[0316] This study includes one main study and one sub-study.
[0317] Main study: 24-week randomized, double-blind, placebo-controlled treatment
[0318] Approximately 186 eligible patients will be selected based on their baseline platelet count (<15×10⁻⁶). 9 / L vs. ≥15×10 9Subjects were stratified and randomized in a 2:1 ratio (HMPL-523:placebo = 2:1) based on their splenectomy history (yes / no) and baseline concomitant anti-ITP therapy (yes / no), and received HMPL-523 or the corresponding placebo 300 mg orally once daily for 24 weeks.
[0319] Regularly evaluate the efficacy and safety of treatments.
[0320] During this stage, PK blood samples will also be collected for analysis of PK characteristics and PK / PD. The impact of treatment on patients' quality of life was evaluated using SF-36.
[0321] Sub-study: 24-week open-label HMPL-523 study design
[0322] Cohort 1: Patients treated for 12 weeks in the main study had platelet counts consistently <50 × 10⁻⁶. 9 Patients who have completed 24 weeks of treatment in the main study (patients already receiving free medication must maintain the same anti-ITP treatment as at the end of the main study) and who, according to investigator assessment, would benefit from HMPL-523 treatment, and who, if determined by investigator to meet the inclusion criteria for the sub-study, may be considered for inclusion in the sub-study to receive open-label HMPL-523 treatment (at the same dose as the treatment received at the end of the main study) until 76 weeks after the last patient in sub-study cohort 2 is enrolled.
[0323] Cohort 2: Enrolled patients with adult ITP (platelet count <30×10⁻⁶ within 24 hours prior to enrollment) 9 / L, disease duration greater than 3 months, and at least one anti-ITP therapy received; HMPL-523 300 mg QD open-label treatment was received until 76 weeks after the last patient in the cohort was enrolled.
[0324] During this phase, PK blood samples may be optionally collected for PK characteristics and PK / PD analysis (only for patients in cohort 1).
[0325] Regularly evaluate the efficacy and safety of treatments.
[0326] Follow-up period:
[0327] Patients will be followed up for 28 days after the last dose of the main study treatment (except for patients who entered the sub-study at 12 weeks of the main study treatment).
[0328] Efficacy was evaluated during the study using platelet count, WHO bleeding score, and the proportion of patients receiving emergency treatment. Safety was assessed through adverse events, laboratory tests, vital signs, and ECG. This study will also evaluate the pharmacokinetic properties of HMPL-523. Furthermore, it will explore the impact of the treatment on patients' quality of life in the main study and the efficacy of HMPL-523 in treating ITP in the sub-study.
[0329] Research Objectives and Endpoints
[0330] Main purpose and endpoint
[0331] The primary objective was to evaluate the efficacy of HMPL-523 in treating adult ITP in the main study, compared with placebo.
[0332] The primary endpoint was sustained response rate, defined as a platelet count ≥50 × 10⁶ in at least four of the six scheduled visits between weeks 14 and 24. 9` The proportion of patients with / L.
[0333] Secondary objectives and endpoints
[0334] 1. Evaluate the efficacy of HMPL-523 during a 24-week double-blind treatment period compared to placebo. Endpoints included: overall response rate within 0–12 weeks (defined as at least one platelet count ≥50 × 10⁻⁶). 9 The proportion of patients with a platelet count of <15×10⁹ / L (excluding those due to emergency treatment); [The percentage of patients with a baseline platelet count <15×10⁹ / L is not specified]. 9 In patients with a platelet count ≥30×10⁶ / L within 0-12 weeks, 9 / L and an increase of ≥20×10 from baseline 9 Percentage of patients with a platelet count of <15 × 10⁹ / L (excluding those with emergency treatment); 9 In patients with / L, a platelet count ≥30×10⁶ within 0-24 weeks 9 / L and an increase of ≥20×10 from baseline 9 Percentage of patients with a platelet count of ≥50 × 10⁶ / L (excluding those due to emergency treatment); Response time (defined as from the start of treatment to the first platelet count ≥50 × 10⁶ / L). 9 / L time (excluding those caused by emergency treatment); incidence and severity of bleeding events assessed according to the WHO bleeding score within 0-12 weeks and 0-24 weeks; platelet count ≥30×10 on two consecutive occasions within 0-24 weeks. 9 The percentage of patients whose dose of ITP is twice the baseline (excluding those due to emergency treatment); the percentage of patients who received pre-defined emergency treatment within 0-24 weeks; and the percentage of patients who reduced or discontinued baseline combined with anti-ITP therapy within 0-24 weeks.
[0335] 2. To evaluate the safety and tolerability of HMPL-523 in a 24-week double-blind treatment regimen compared to placebo. Endpoints: adverse events (AEs), clinical laboratory tests, vital signs, physical examination, and electrocardiogram (ECG); 3. Evaluate the pharmacokinetic (PK) characteristics of HMPL-523 in adult ITP patients in China. Endpoint: Steady-state plasma concentrations of HMPL-523 and its major metabolites at 2 and 4 hours after administration (C0). 2h,ss C 4h,ss ) and steady-state valley concentration (C min,ss )wait Exploratory purpose and endpoint 1. To assess the impact of HMPL-523 treatment on the quality of life of adult ITP patients in China during the main study. Endpoint: At baseline, week 12, week 24, or at the end of double-blind treatment, quality of life was assessed using the SF-36 Health Survey (SF-36) scale based on physical functioning, general health status, social functioning, and emotional effects to determine the extent of improvement in quality of life compared to baseline.
[0336] 2. Pharmacokinetic / pharmacodynamic (PK / PD) relationship between drug exposure and platelet response Endpoint: Steady-state C min The relationship between efficacy indicators and other indicators.
[0337] 3. Long-term safety of HMPL-523 in treating adult ITP in a sub-study. Endpoints: adverse events (AEs), clinical laboratory tests, vital signs, physical examination, and electrocardiogram (ECG); 4. In the sub-study, the sustained efficacy of HMPL-523 in treating adult ITP. Endpoint: In the sub-study, a first platelet count ≥50 × 10⁻⁶. 9 Within 12 weeks after / L, platelet count <50×10 9 The percentage of patients with ≤2 doses (at least 2 weeks apart) of / L (excluding those induced by emergency treatment).
[0338] Research Evaluation
[0339] efficacy assessment
[0340] The efficacy was evaluated using platelet count, WHO bleeding score, and the proportion of patients receiving emergency treatment. Efficacy was assessed every two weeks during the treatment period.
[0341] Security assessment
[0342] After obtaining informed consent, the safety of all recruited patients must be closely monitored until 28 days after the last dose, or until the patient withdraws informed consent and refuses subsequent safety visits, whichever comes first. All serious adverse events (SAEs) must be collected from the time of informed consent signing until the first dose; all AEs / SAEs must be collected from the time of the first dose until 28 days after the last dose; and any SAEs reasonably likely to be related to the investigational drug that are confirmed by the investigator must be reported after 28 days after the last dose or after the end of study treatment and the initiation of other anti-ITP therapy. All deaths occurring within 28 days of the last dose must be reported as SAEs. Adverse events will be classified according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCICTCAE version 5.0).
[0343] Pharmacokinetic assessment
[0344] The detection of HMPL-523 and its metabolites in blood samples will be performed in the central laboratory. Blood sample collection, storage, and transport will be described in detail in the laboratory manual. Bioanalytical methods and experimental procedures will be described in detail in the clinical study report. The primary assessment is the steady-state pharmacokinetic characteristics of HMPL-523 and its metabolites in ITP patients. PK blood samples will be collected from all patients in the main study; in the sub-study, samples will only be collected from eligible informed consent patients who have signed up for PK blood collection.
[0345] Quality of life assessment
[0346] The study will evaluate the impact of treatment on patients' quality of life using SF-36.
[0347] Video visit rate
[0348] During the screening period, patients must go to the research center for basic information collection and baseline assessment of efficacy and safety indicators.
[0349] During the screening process, patients will undergo basic information collection and baseline assessment of efficacy and safety indicators at the research center.
[0350] The primary study duration was 24 weeks. Patients underwent efficacy and safety assessments at weeks 1 and 2, and every 2 weeks from week 2 (excluding week 2) to week 24. Specifically, 12-lead ECG, blood biochemistry, urinalysis, and stool analysis were performed every 4 weeks; pregnancy testing was performed every 4 weeks; and the SF-36 scale assessment was conducted at baseline, week 12, week 24, or at the end of the double-blind treatment. PK specimens were collected every 2 weeks from week 1 to week 8.
[0351] In sub-cohort 1, efficacy and safety assessments were conducted every 4 weeks from week 1, week 4, and week 4 (excluding week 4) until the end of treatment. Pregnancy trials were assessed every 4 weeks. In cohort 2, efficacy and safety assessments were conducted every 4 weeks for the first 24 weeks (inclusive), and then every 8 weeks thereafter. PK specimens could be collected from week 1 to week 8 (only for sub-cohort 1).
[0352] The follow-up period for this study was 4 weeks. Patients were required to return to the research center for follow-up every week for 4 weeks after the last dose.
[0353] Researchers may conduct unplanned visits whenever necessary during the research period.
[0354] Study population
[0355] Main study and sub-cohort 1: Adults diagnosed with chronic primary ITP (duration ≥12 months); mean platelet count <30×10⁻⁶ at three visits within 3 months prior to randomization. 9 / L, and each time <35×10 9 Patients with a blood alcohol content of 6L; those who have previously received one or more anti-ITP therapies with an inadequate response or who have relapsed after treatment.
[0356] Sub-cohort 2: Enrolled patients with human immune thrombocytopenic purpura (pre-enrollment platelet count <30×10⁻⁶) 9 / L, disease duration greater than 3 months, and at least one prior anti-ITP treatment).
[0357] Main study inclusion / exclusion criteria
[0358] Selection criteria:
[0359] Patients must meet all of the following criteria to be eligible for selection:
[0360] 1. Voluntary signing of ICF; 2. Men or women aged 18 to 75; 3. Performance status score [Eastern Cooperative Oncology Group (ECOG) score] 0-1; 4. The patient had been diagnosed with primary ITP prior to randomization, and the duration of the disease exceeded 12 months; 5. Failure to respond to at least one standard anti-ITP drug (including glucocorticoids, immunoglobulins, and eltrombopag (or drugs with the same mechanism of action) or relapse after treatment. Ineffectiveness is defined as a platelet count <30 × 10⁻⁶ after treatment. 9 / L, or platelet count <2 times baseline, or bleeding; relapse is defined as a platelet count <30×10⁹ / L again after effective treatment. 9 / L, or platelet count < 2 times baseline, or bleeding; 6. The patient must have a history of response to ITP treatment; 7. This study allows for concomitant anti-ITP therapy. If a patient receives concomitant anti-ITP therapy, the following criteria must be met: a. Glucocorticoids: Daily dose <20 mg prednisone equivalent, and the dose has been stable for 4 weeks prior to randomization; b. Danazol: Stable dose for 3 months prior to randomization; c. Immunosuppressants: Only one of the following drugs is permitted: azathioprine, cyclosporine A, or mycophenolate mofetil, and the drug must have been at a stable dose for 3 months prior to randomization.
[0361] 8. The condition is relatively stable, with a WHO bleeding grade of 0-1, and researchers have determined that no emergency treatment is expected within 2 weeks; 9. Laboratory tests meet the following criteria (no treatment for this indicator has been received within one week prior to blood collection): a. The average of three platelet counts within three months prior to the randomization date is <30 × 10⁻⁶. 9 / L, and each time ≤35×10 9 / L, of which one is the most recent test result that the patient can provide 28 days prior to randomization (except for those caused by emergency treatment), and the other two are tests conducted during the screening period with an interval of at least 3 days. The first test during the screening period must be completed at least 4 days prior to randomization (except for those caused by emergency treatment). b. Hemoglobin ≥100 g / L, neutrophil count >1.5×10 9 / L; c. Total bilirubin (TBIL), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ≤ 1.5 × upper limit of normal reference range (ULN); d. Serum creatinine concentration ≤1.5×ULN, and creatinine clearance ≥50 mL / min; e. Serum amylase and lipase ≤1.5×ULN; f. The International Normalized Ratio (INR) and Activated Partial Thromboplastin Time (APTT) values did not exceed 20% of the normal range.
[0362] 10. Male or female patients of childbearing potential must agree to use an effective method of contraception, such as a double barrier method, condom, oral or injectable contraceptive, intrauterine device, etc., during the study period and for 90 days after the last study dose. This condition does not apply to postmenopausal women (>50 years of age and last menstruation for more than 1 year) and women who have undergone surgical sterilization.
[0363] Exclusion criteria:
[0364] If any of the following criteria are met, the candidate must be excluded from this study:
[0365] 1. There is existing evidence that the patient has a history of secondary causes of ITP (e.g., untreated Helicobacter pylori infection, leukemia, lymphoma, common variable immunodeficiency, systemic lupus erythematosus, autoimmune thyroid disease) or drug treatment (e.g., heparin, quinine, antimicrobial drugs, anticonvulsants), or multiple immune cytopenias (e.g., Evans syndrome); 2. If the patient experiences severe clinical bleeding, immediate platelet adjustment is required (e.g., menorrhagia accompanied by a significant decrease in hemoglobin). 3. Patients who have experienced symptomatic gastrointestinal bleeding (such as hematemesis or melena) within 6 months prior to the screening visit, but a positive occult blood test without any signs or symptoms of gastrointestinal bleeding is not considered "symptomatic" or hemorrhoidal bleeding is excluded. 4. The patient has a history of major organ transplantation or hematopoietic stem cell / bone marrow transplantation; 5. The patient was vaccinated within the first 8 weeks of randomization; or plans to be vaccinated during the study. 6. Individuals who underwent splenectomy within the preceding 12 weeks; 7. Individuals who have undergone major surgery within the four weeks prior to randomization, or who require major elective surgery during the study period; 8. Those with a history of malignant tumors (excluding cured basal cell carcinoma of the skin or cervical carcinoma in situ); 9. History of significant arterial / venous thrombotic disease; 10. History of intracranial hemorrhage or severe bleeding in other vital organs; 11. History of severe cardiovascular disease (such as congestive heart failure of grade III / IV, arrhythmia or angina requiring drug treatment, unstable angina, coronary artery stenting, angioplasty or coronary artery bypass grafting, or corrected QT interval (QTc) ≥450 ms). 12. Hypertension that cannot be controlled by medication (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg); 13. Individuals with severe gastrointestinal diseases such as dysphagia or active gastric ulcers who are unable to take oral medications or have malabsorption of oral medications; 14. Human immunodeficiency virus (HIV) infection, or hepatitis B [if hepatitis B surface antigen [HBsAg] or hepatitis B core antibody [HBcAb] is positive, it is necessary to confirm that hepatitis B virus deoxyribonucleic acid (HBV DNA) is positive], or hepatitis C [hepatitis C virus ribonucleic acid (HCV RNA) positive], or cirrhosis; 15. Clinically uncontrolled significant active infection (e.g., sepsis, pneumonia, or abscess), or a serious infection (leading to hospitalization or requiring antibiotic treatment) within 6 weeks prior to randomization; 16. Those who have received intravenous immunoglobulin or platelet transfusion within 2 weeks prior to randomization, or who have received other treatments aimed at increasing platelet count (including but not limited to glucocorticoids, thrombopoietin, thrombopoietin receptor agonists, cyclosporine A, mycophenolate mofetil, etc.) within 4 weeks prior to randomization, and who meet inclusion criterion 7, are excluded. 17. Individuals who received rituximab treatment within the 14 weeks prior to randomization; 18. Individuals who received traditional Chinese medicine treatment within the week prior to randomization; 19. Patients who require long-term / continuous treatment with medications that affect platelet function (including but not limited to aspirin, clopidogrel, ticagrelor, nonsteroidal anti-inflammatory drugs (NSAIDs), etc.) or anticoagulants. 20. Administer strong CYP3A inhibitors or inducers (three weeks for St. John's wort) for the first two weeks or five half-lives (whichever is longer) at random. 21. Individuals who participated in clinical trials of drugs or invasive medical devices within 4 weeks prior to randomization (or within 5 half-lives of the investigational drug prior to randomization, whichever is longer); 22. Previous treatment with a spleen tyrosine kinase Syk inhibitor (such as fantatinib); 23. Individuals with known allergies to the active ingredient or excipients of the investigational drug; 24. The patient has severe psychological or mental abnormalities; 25. Alcoholics or drug abusers; 26. Female patients who are pregnant or breastfeeding; 27. The researchers believe that the patient is not suitable to participate in this study.
[0366] Sub-study Entry / Exclusion Criteria
[0367] Selection criteria:
[0368] Only for Cohort 1 (patients who previously received the main study treatment):
[0369] Patients must meet all of the following criteria to be eligible for selection:
[0370] 1. Voluntary signing of the sub-research ICF; 2. Physical condition score (ECOG rating) 0-1 point; 3. The condition is relatively stable, with a WHO bleeding grade of 0-1, and researchers have determined that no emergency treatment is expected within 2 weeks; 4. The types, dosages, or frequencies of combined anti-ITP treatments did not increase compared to the main study; 5. Patients who have received the main study treatment for 12 weeks and whose platelet count remains <50×10⁻⁶ during this period. 9 / L (If the main study patient received emergency treatment during the treatment period, the platelet count must be <50×10⁻⁶ before enrollment) 9 Patients must either have received the primary study treatment ( / L) or have received at least 24 weeks of treatment (patients already receiving the free drug must maintain consistent anti-ITP treatment with the treatment received at the end of the primary study), and the investigator must assess that the patient would benefit from the current study treatment. Benefit is defined as: sustained response patients (platelet count ≥50 × 10⁶ / L in at least 4 out of 6 visits during W14 to W24). 9 / L), or those who have sustained clinical benefit (platelet count ≥30×10 in at least 4 out of 6 visits during W14 to 24). 9 / L and increased by 20×10 compared to baseline. 9 / L); or the bleeding score has improved; 6. The interval between the W12 visit date in the primary study and the first dosing date in the sub-study is expected to be ≤7 days, even if the platelet count does not decrease to <50×10⁻⁶ due to emergency treatment received during the primary study. 9 Patients with / L may have their treatment extended to 14 days (only for patients who have completed 12 weeks of treatment in the main study and are now entering the sub-study); 7. Laboratory tests within 7 days (inclusive) prior to enrollment in the sub-study must meet the following conditions: a. Hemoglobin ≥100 g / L, neutrophil count >1.5×10 9 / L; b. TBIL, ALT, and AST ≤ 1.5 × ULN; c. Serum creatinine concentration ≤1.5×ULN, and creatinine clearance ≥50 mL / min; d. Serum amylase and lipase ≤1.5×ULN; The e.INR and APTT values did not exceed 20% of the normal range.
[0371] 8. Female patients of childbearing potential must agree to use highly effective contraception from screening until 30 days after the end of study treatment. They must also agree not to donate eggs (oocytes) for reproductive purposes during this period. Subjects must not be breastfeeding, and pregnancy test results must be negative (if of childbearing potential).
[0372] 9. Male patients whose female partners are of fertility must agree to use barrier contraception during the study period and for 30 days after the termination of study treatment. Subjects should avoid donating or freezing sperm from the start of treatment until 30 days after the termination of study treatment.
[0373] For queue 2 only:
[0374] Patients must meet all of the following criteria to be eligible for selection:
[0375] 1. Voluntary signing of the sub-research ICF; 2. Men or women aged 18-75; 3. Physical condition score (ECOG score): 0-1 point; 4. The patient's condition is relatively stable, with a WHO bleeding grade of 0-1; 5. Platelet count < 30 × 10⁻⁶ within 24 hours prior to enrollment. 9 / L, disease duration greater than 3 months, and at least one anti-ITP treatment received; 6. Laboratory tests within 7 days (inclusive) prior to enrollment in the sub-study must meet the following criteria (no treatment for abnormal indicators received within 1 week prior to blood collection): a. Hemoglobin ≥ 90 g / L, neutrophil count > 1.5 × 10⁻⁶ 9 / L; b. TBIL, ALT, and AST ≤ 1.5 × ULN; c. Serum creatinine concentration ≤1.5×ULN, and creatinine clearance ≥50 mL / min; d. Serum amylase and lipase ≤1.5×ULN; The e.INR and APTT values did not exceed 20% of the normal range.
[0376] 7. This study allows for concomitant anti-ITP treatment, with no restrictions on the type, amount, or dosage of treatment, but a stable dose must be maintained for 4 weeks before enrollment (of which the stable dose of glucocorticoids must be maintained for 2 weeks); 8. Female patients of childbearing potential must agree to use highly effective contraception from screening until 30 days after the end of study treatment. They must also agree not to donate eggs (oocytes) for reproductive purposes during this period. Subjects must not be breastfeeding, and pregnancy test results must be negative (if of childbearing potential).
[0377] 9. Male patients whose female partners are of fertility must agree to use barrier contraception during the study period and for 30 days after the termination of study treatment. Subjects should avoid donating or freezing sperm from the start of treatment until 30 days after the termination of study treatment.
[0378] Exclusion criteria:
[0379] For Cohort 1 only (patients who previously received the main study treatment):
[0380] Subjects meeting any of the following criteria must be excluded from this study:
[0381] 1. Those who received the main study treatment for less than 12 weeks due to reasons other than lack of efficacy; 2. Vaccinated within 8 weeks prior to randomization up to day 1 (baseline visit); or planned to be vaccinated during the study; 3. History of significant arterial / venous thrombotic disease; 4. History of severe cardiovascular disease (such as grade III / IV congestive heart failure, arrhythmia or angina requiring medication, unstable angina, coronary artery stenting, angioplasty or coronary artery bypass grafting, or QTc ≥450 ms); 5. Clinically uncontrolled significant active infection (e.g., sepsis, pneumonia, or abscess), or a serious infection (leading to hospitalization or requiring antibiotic treatment) within 6 weeks prior to randomization; 6. Hypertension that cannot be controlled by medication (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg); 7. Those who have received blood transfusions or blood products (except for IVIg used for emergency treatment) within 2 weeks prior to enrollment; 8. Patients who require long-term / continuous treatment with medications that affect platelet function (including but not limited to aspirin, clopidogrel, ticagrelor, NSAIDs, etc.) or anticoagulants; 9. Administer a strong CYP3A inhibitor or inducer for the first two weeks (three weeks for St. John's wort) or five half-lives (whichever is longer) before randomization; 10. Individuals with a known allergy to the active ingredient or excipients of the investigational drug; 11. The patient has severe psychological or mental abnormalities; 12. Alcoholics or drug abusers; 13. Female patients who are pregnant or breastfeeding; 14. The researchers believe that the patient is not suitable to participate in this study.
[0382] For queue 2 only:
[0383] If any of the following criteria are met, the candidate must be excluded from this study:
[0384] 1. Existing evidence suggests that the patient has a secondary cause of ITP; 2. Patients who have experienced symptomatic gastrointestinal bleeding (such as hematemesis or melena) within 6 months prior to the screening visit, but a positive occult blood test without any signs or symptoms of gastrointestinal bleeding is not considered "symptomatic" or hemorrhoidal bleeding is excluded. 3. The patient has a history of major organ transplantation or hematopoietic stem cell / bone marrow transplantation; 4. Vaccinated within 8 weeks prior to randomization up to day 1 (baseline visit); or planned to be vaccinated during the study; 5. Individuals who underwent splenectomy within the preceding 12 weeks; 6. Individuals who have undergone major surgery within the four weeks prior to randomization, or who require major elective surgery during the study period; 7. Those with a history of malignant tumors (excluding cured basal cell carcinoma of the skin or cervical carcinoma in situ); 8. History of significant arterial / venous thrombotic disease; 9. History of intracranial hemorrhage or severe bleeding in other vital organs; 10. History of severe cardiovascular disease (such as congestive heart failure of grade III / IV, arrhythmia or angina requiring drug treatment, unstable angina, coronary artery stenting, angioplasty or coronary artery bypass grafting, or corrected QT interval (QTc) ≥450 ms); 11. Hypertension that cannot be controlled by medication (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg); 12. History of severe gastrointestinal diseases such as dysphagia, active gastric ulcers, etc., which prevent oral medication or cause malabsorption of oral medication; 13. Individuals with human immunodeficiency virus (HIV) infection, hepatitis B (if HBsAg or HBcAb is positive, HBV DNA positivity must be confirmed), hepatitis C (HCV RNA positive), or cirrhosis. 14. Clinically uncontrolled significant active infection (e.g., sepsis, pneumonia, or abscess), or a serious infection (leading to hospitalization or requiring antibiotic treatment) within 6 weeks prior to randomization; 15. Individuals who received rituximab treatment within the 14 weeks prior to randomization; 16. Individuals who received traditional Chinese medicine treatment with a clear platelet-raising function within one week prior to randomization; 17. Patients who require long-term / continuous treatment with medications that affect platelet function (including but not limited to aspirin, clopidogrel, ticagrelor, NSAIDs, etc.) or anticoagulants. 18. Randomize for two weeks (three weeks for St. John's wort) or five half-lives (whichever is longer) of strong CYP3A inhibitors or inducers, as well as sensitive or narrow therapeutic window substrates of CYP3A, CYP1A2 or CYP2B6. 19. Individuals who participated in clinical trials of drugs or invasive medical devices within 4 weeks prior to randomization (or within 5 half-lives of the investigational drug prior to randomization, whichever is longer); 20. Individuals with a known allergy to the active ingredient or excipients of the investigational drug; 21. The patient has severe psychological or mental abnormalities; 22. Alcoholics or drug abusers; 23. Female patients who are pregnant or breastfeeding; 24. The researchers believe that the patient is not suitable to participate in this study.
[0385] Restrictions during the research period
[0386] During the study, patients are not allowed to consume grapefruit or grapefruit juice, and should not consume large amounts of grapefruit and lime (and other products containing these fruits, such as grapefruit juice or marmalade). The daily intake should not exceed one small cup (120 mL) of grapefruit juice or half a grapefruit, or one to two tablespoons (15 g) of marmalade. Drug use or excessive alcohol consumption is prohibited.
[0387] Research on treatment
[0388] Research drugs
[0389] HMPL-523 acetate tablets or HMPL-523 placebo are pale yellow tablets available in strengths of 100 mg and 150 mg; packaged in white high-density polyethylene bottles containing 30 tablets per bottle, and stored below 25°C.
[0390] Administration method
[0391] Patients must receive medication at the research center on each visit day.
[0392] HMPL-523 tablets or HMPL-523 placebo tablets are recommended to be taken with approximately 240 mL of warm water within 30 minutes after a meal.
[0393] During the study, every effort should be made to ensure that patients take medication according to the study protocol. It is recommended to administer medication at the same time each day. If a patient misses a dose of the study medication for any reason more than 12 hours, they should not take a make-up dose and should continue to take the medication at the scheduled dose at the next scheduled time. If a patient vomits after taking medication, it is not recommended to take a make-up dose unless the whole tablet is seen. Missed doses or vomiting after medication must be recorded.
[0394] Main research
[0395] Eligible patients were randomly assigned to either the HMPL-523 group or the placebo group, receiving 300 mg of HMPL-523 or placebo orally once daily (QD) for 24 weeks.
[0396] Sub-studies
[0397] Cohort 1: Patients treated for 12 weeks in the main study had platelet counts consistently <50 × 10⁻⁶. 9 Patients who have completed 24 weeks of treatment in the main study (patients already receiving free treatment must maintain the same anti-ITP therapy as at the end of the main study) and who, according to investigator assessment, would benefit from the current study treatment, and who, if determined by investigators to meet the inclusion criteria for a sub-study, may be considered for inclusion in the sub-study to receive open-label HMPL-523 treatment (at the same dose as their current treatment). Treatment in sub-study cohort 1 can continue for up to 76 weeks after the last patient in sub-study cohort 2 is enrolled in the sub-study.
[0398] Cohort 2: Enrolled patients with adult ITP (platelet count < 30 × 10⁻⁶ within 24 hours prior to enrollment) 9 / L, disease duration greater than 3 months, and at least one anti-ITP therapy received, and were treated with HMPL-523 300 mg QD open-label therapy until 76 weeks after the last patient in the cohort was enrolled.
[0399] Study drug dosage adjustment
[0400] Recommendations for adjusting the dosage of research drugs due to adverse events:
[0401] If any of the following drug-related adverse events (CTCAE v5.0) occur, HMPL-523 administration may be temporarily suspended. If the adverse event returns to baseline or is ≤ Grade 1 within 14 days of discontinuation, administration may be resumed at a reduced dose level; otherwise, permanent discontinuation is required. The following dose reduction guidelines are for reference: it is recommended to reduce the dose sequentially at 200 mg, then 100 mg dose levels, or consider dividing the dose into two doses while maintaining the same total daily dose. If a dose reduction is due to a drug-related adverse event, the HMPL-523 dose may be reinstated after the event has resolved, subject to investigator evaluation.
[0402] Grade 3 or higher lung infection Grade 3 or higher neutropenia Symptomatic interstitial lung disease Pancreatitis requiring treatment intervention Kidney dysfunction requiring treatment intervention Other significant adverse events as determined by researchers Recommendations for adjusting the dosage of investigational drugs if an increase in platelet count occurs during treatment: When the platelet count is ≥250×10 9 / L for 2 consecutive weeks or any single platelet count ≥400×10 9 / L, the dosage of the study drug can be reduced, successively to 200 mg and 100 mg.
[0403] Combined medication
[0404] Combined anti-ITP therapy
[0405] Patients in the main study and sub-cohort 1 are permitted a maximum of one concomitant anti-ITP therapy during the study period, provided they meet the following criteria: Glucocorticoids (<20 mg prednisone equivalent) were administered at a stable dose for 4 weeks prior to randomization. Danazol had been at a stable dose for 3 months prior to randomization. Immunosuppressants (including only one of azathioprine, cyclosporine A, and mycophenolate mofetil) were at a stable dose for 3 months prior to randomization.
[0406] Patients in sub-cohort 2 were allowed to receive concurrent anti-ITP therapy during the study period, with no restrictions on the type, amount, or dosage of treatment, but they needed to maintain a stable dose for 4 weeks before enrollment (of which the stable dose of glucocorticoids was for 2 weeks).
[0407] Anti-ITP treatment dose adjustment rules during the study: Dosage adjustments are only permitted by dose reduction or discontinuation; dose increases are not allowed and will be considered emergency treatment. Reduction of concomitant anti-ITP therapy may be considered if the platelet count meets the following criteria during the study: Platelet count ≥100×10 9 / L lasted for 4 weeks Platelet count ≥250×10 9 / L lasts for 2 weeks; Emergency treatment The protocol allows for emergency treatments including platelet transfusion, intravenous immunoglobulin (IVIg), and glucocorticoid pulse therapy. When patients require emergency treatment during the study, IVIg is recommended as the first-line treatment; glucocorticoid pulse therapy is generally not recommended unless absolutely necessary.
[0408] Patients may receive emergency treatment at any time during the study period if the investigators deem it necessary. Patients who receive emergency treatment are considered unresponsive during the course of treatment and remain so until the emergency treatment ends and their platelet count is <50 × 10⁻⁶. 9 / L.
[0409] Statistical analysis and sample size calculation
[0410] Estimation of sample size
[0411] The calculation of the main study sample size is based on the following assumptions: The response rate in the HMPL-523 treatment group was 18% at the primary endpoint; The response rate in the placebo group at the primary endpoint was 2%. The overall significance level was 0.025 for one-sided cases. The test power is 90%; The shedding rate was 15%; The randomization ratio was 2:1 for the treatment group and the control group. Based on the above assumptions, the main study is expected to include 186 patients, who will be randomly assigned in a 2:1 ratio to the HMPL-523 group (124 patients) and the placebo group (62 patients). Sample size will be calculated using PASS 11 based on the Mantel-Haenszel test.
[0412] Based on clinical trial results of other Syk inhibitors, the proportion of patients randomly assigned to either sorapinib or placebo that met the primary endpoint was assumed to be 18% or 2%, respectively. Under this assumption, combined with a 2:1 allocation ratio and a 20% dropout rate, a sample size of 186 patients with primary ITP was estimated (124 for the sorapinib group and 62 for the placebo group) to provide 90% efficacy, allowing rejection of the null hypothesis at a two-sided significance level of α = 0.05.
[0413] All efficacy endpoints were assessed in the intention-to-treat (ITT) analysis set, defined as all randomized patients. Sensitivity analysis of the primary endpoint was performed in the per-protocol group (PPS), defined as patients in the ITT analysis group who did not have any significant protocol deviations that could affect the assessment of the primary endpoint. The safety analysis group included patients who received at least one treatment during the treatment period.
[0414] Platelet counts affected by emergency treatment are not used to derive efficacy endpoints.
[0415] For the primary endpoint, the exact 95% CIs of response rate were calculated using the Clopper-Pearson method, and the Cochran-Mantel-Haenszel chi-square test was used to analyze differences between treatment groups, with adjustments made for stratification factors. In the sensitivity analysis, Fisher's exact test was used to assess differences in the primary endpoint between treatment groups. Group analysis was performed for the primary endpoint, considering factors including sex, baseline platelet count, prior splenectomy, prior use of TPO and / or TPO-RA, and concurrent anti-ITP therapy at baseline.
[0416] Key secondary endpoints of platelet count response and dichotomous variables (the proportion of patients receiving pre-specified emergency treatment during the 24-week double-blind treatment period, and the proportion of patients reducing or discontinuing anti-ITP concomitant therapy at baseline) were calculated using the Clopper-Pearson method and analyzed using the Cochran-Mantel-Haenszel test. The severity of bleeding events was categorized according to the WHO Bleeding Scale, which uses a dichotomy to represent no bleeding (grade 0 = 0) and bleeding (grade 1 = 1, 2, 3, or 4). The mean WHO bleeding score at all post-baseline visits was analyzed during the first 12 and 24 weeks of double-blind treatment, and the incidence of bleeding events was summarized by visit. Differences in WHO bleeding scores between treatment groups were analyzed using an analysis of covariance (ANCOVA) model, which included baseline WHO bleeding grade and randomization stratification factors as covariates. For the secondary endpoint of time to event occurrence (response time), the median and 95% CI were estimated using the Kaplan-Meier method.
[0417] A post-hoc analysis was performed on the primary endpoint, taking into account previous treatment regimens and prior use of anti-CD20 antibodies. To further characterize the post-treatment platelet increase, the median platelet counts at baseline and planned visits during the double-blind period were calculated for continuous responders (meeting the primary endpoint criteria) and patients in both treatment groups. Post-treatment assessments were performed weekly for 4 weeks following the completion of treatment.
[0418] To address the differences in baseline WHO bleeding score characteristics between the two patient groups, post-hoc analyses were performed on bleeding events based on baseline WHO bleeding scores and various comprehensive analyses. Furthermore, for patients reporting grade ≥3 bleeding and severe bleeding, post-hoc analyses of major bleeding events were performed according to the International Society for Thrombosis and Haemostasis (ISTH) criteria. These criteria include life-threatening bleeding and / or symptomatic bleeding in vital sites or organs, such as intracranial, spinal, intraocular, retroperitoneal, intra-articular, or intraperitoneal, or intramuscular bleeding with ventricular septal syndrome, and / or resulting in a decrease in hemoglobin levels of 1.24 mmol / L (≥20 g / L) or greater, or resulting in a transfusion of ≥2 units of whole blood or red blood cells.
[0419] A p-value < 0.05 was considered statistically significant; p-values for secondary endpoints and subgroup analyses were nominal values. All statistical analyses were performed using SAS version 9.4 software. This study was registered at ClinicalTrials.gov (NCT05029635).
[0420] Research Results
[0421] Between September 29, 2021 and December 31, 2022, a total of 236 patients were screened, and 188 patients were randomly assigned to either the sorapinib group (n=126) or the placebo group (n=62). All randomized patients were included in the ITT and safety analysis sets.
[0422] As of the data cutoff date (July 14, 2023), 87 patients (69.0%) in the solepinib group completed the 24-week study treatment, compared to only 8 patients (12.9%) in the placebo group. Overall, 99 patients (78.6%) in the solepinib group and 53 patients (85.5%) in the placebo group received open-label treatment. During the initial 12 weeks of treatment, 31 patients in the solepinib group and 51 patients in the placebo group did not respond to the treatment. Of these, 26 patients (83.9%) and 49 patients (96.1%) in the two groups, respectively, prematurely ended the double-blind treatment and received open-label solepinib. During the double-blind treatment period, the median treatment exposure time was 24.1 weeks (IQR 12.4–24.3) in the solepinib group and 12.1 weeks (IQR 12.0–12.9) in the placebo group.
[0423] The baseline characteristics of the two groups of patients were largely similar (Table 3). Most patients had chronic ITP ≥ 3 years (75.4% [95 / 126] of patients received sorepinib, 82.3% [51 / 62] of patients received placebo), had received numerous prior lines of therapy (median 4.0 vs 4.0), and had received thrombopoietin (TPO) / TPO receptor agonist (TPO-RA) therapy (74.6% [94 / 126] vs 64.5% [40 / 62]). Twenty (15.9%) patients in the sorepinib group and seven (11.3%) patients in the placebo group had previously received anti-CD20 antibody therapy. More than half of the patients had a baseline WHO bleeding scale score of 1, a higher proportion in the sorepinib group compared to the placebo group (69.0% [87 / 126] vs 53.2% [33 / 62]). At baseline, 85 (67.5%) patients in the sorapinib group and 42 (67.7%) patients in the placebo group did not receive concomitant anti-ITP treatment.
[0424] Compared with placebo, sorapinib had a significantly higher sustained response rate to the primary endpoint (48.4% [61 / 126] vs 0% [0 / 62], Cochran-Mantel-Haenszel test p<0.0001; response difference 48.3% [95% CI 39.6–57.1]; Table 4). Post-hoc analysis showed that the median platelet count in the sorapinib group (≥50 × 10⁻⁶) was significantly higher in all post-baseline visits. 9 / L to ≥90×10 9 The percentages ( / L) were all higher in the placebo group (<30×10⁻⁶). 9 The median platelet count in sustained responders in the sorapinib group ranged from 80 to 100 × 10⁹ / L. 9 / L (Figure 2). Of the 61 continuous respondents, 51 (83.6%) responded ≥5 times in 6 visits between weeks 14 and 24, and 39 (63.9%) responded in all 6 visits. All sensitivity analyses in the ITT and PPS datasets showed results consistent with the primary endpoint analyses.
[0425] Secondary efficacy endpoints are shown in Table 4. Most secondary endpoints were favorable to the sorapinib group. Compared with placebo, the overall response rate of sorapinib was significantly higher at weeks 0–12 (68.3% vs 14.5%, p<0.0001) and 0–24 (70.6% vs 16.1%, p<0.0001). During the double-blind period, patients treated with sorapinib had significantly less use of emergency medications compared with those treated with placebo (22.2% vs 35.5%, p=0.0451).
[0426] Compared with patients receiving placebo, patients receiving solepinib had a higher proportion of those who reduced or discontinued baseline concomitant anti-ITP therapy, but the difference was not statistically significant (26.8% vs 10.0%, p=0.1471).
[0427] Compared with the placebo group, the sorapinib group had a faster treatment response, with a median time to response of 1.1 weeks, compared with 4.3 weeks in the placebo group.
[0428] Over 24 weeks, the incidence of WHO bleeding scores decreased in the sorapinib group. At weeks 0–12 (least square mean: 0.6 vs 0.8, p=0.0019) and 0–24 (0.6 vs 0.8, p=0.0002), the mean WHO bleeding score in the sorapinib group was significantly lower than that in the placebo group. The incidence of ≥ grade 3 bleeding was lower in the sorapinib group compared to placebo (7 [5.6%] vs 6 [9.7%]).
[0429] Eleven patients (8.7%) using sorapinib and five patients (8.1%) using placebo reported serious bleeding. Post-hoc analysis showed that for patients with a baseline WHO bleeding score of 1, the incidence of bleeding grade ≥3 was lower in the sorapinib group than in the placebo group (6 [6.9%] vs 5 [15.2%]). For patients reporting bleeding grade ≥3 and serious bleeding, the incidence of major bleeding events was lower in the sorapinib group than in the placebo group according to ISTH criteria (≥3: 2 [1.6%] vs 5 [8.1%]; severity: 2 [1.6%] vs 4 [6.5%]).
[0430] In most predefined subgroups, the sustained response rate results were consistent, showing a higher sustained response rate of sorapinib compared to the placebo group; however, the subgroup of patients who had previously undergone splenectomy was an exception due to its small sample size. In the subgroup of patients who had previously received TPO / TPO-RA therapy, the sustained response rate in the sorapinib group (46.8%, 44 / 94) was significantly higher than that in the placebo group (0%, 0 / 40) (P<0.0001; response difference 46.8% [95% CI 36.1–57.6]).
[0431] Post-hoc analysis of sustained response rates in patients who had received four or more prior lines of therapy (47.7% [42 / 88] vs 0%], p<0.0001) and patients who had previously received anti-CD20 antibody therapy (50.0% [10 / 20] vs 0%], p=0.0261) also showed that solepinib was superior to placebo.
[0432] SF-36-based quality of life analysis showed that, during the double-blind treatment period, sorepinib significantly improved two of the eight domains compared to placebo: physical function (mean least squares difference: 5.61, P = 0.0346) and energy / fatigue (mean least squares difference: 6.09, P = 0.0340) (Table 5). Four of the eight domains (role limitation due to physical health, role limitation due to emotional problems, emotional health, and general health) showed a trend toward improvement with sorepinib, but this was not statistically significant. Patients receiving sorepinib showed a significant difference in pain (mean least squares difference: -5.95, P = 0.0360) (Table 5).
[0433] In the sorepinib group, 125 patients (99.2%) and in the placebo group, 53 patients (85.5%) experienced any grade of TEAE, with most TEAEs being mild or moderate (grade 1 or 2). A total of 32 patients (25.4%) in the sorepinib group reported ≥ grade 3 TEAEs, compared to 15 patients (24.2%) in the placebo group. Serious TEAEs occurred in 26 patients (20.6%) in the sorepinib group and 11 patients (17.7%) in the placebo group, with only 2 (1.6%) and 1 (1.6%) patients experiencing treatment-related serious TEAEs: one patient receiving sorepinib experienced limb pain (grade 2) and maculopapular rash (grade 1), and another patient experienced hypertension (grade 3); one patient receiving placebo experienced cerebral hemorrhage (grade 3).
[0434] No deaths occurred during the study. Table 6 lists the TEAEs that occurred in 10% or more of the patients. The most common TEAEs were upper respiratory tract infection (36 [28.6%] patients treated with sorapinib, 6 [9.7%] patients treated with placebo), COVID-19 infection (30 [23.8%] patients vs 8 [12.9%] patients), and elevated blood lactate dehydrogenase (30 [23.8%] patients vs 4 [6.5%] patients).
[0435] According to reports, 15 patients (11.9%) taking sorepinib developed hypertension, and 3 patients (4.8%) taking placebo developed hypertension. In the sorepinib group, 4 patients (3.2%) developed grade 3 hypertension, and only 1 patient (0.8%) reported a serious case.
[0436] At baseline, 3 (2.4%) patients in the sorapinib group and 2 (3.2%) patients in the placebo group had systolic blood pressure ≥140 and <160 mmHg, and / or diastolic blood pressure ≥90 and <100 mmHg. After baseline, 42 (33.3%) patients in the sorapinib group and 20 (32.3%) patients in the placebo group had systolic blood pressure ≥140 mmHg and / or diastolic blood pressure ≥90 mmHg; 8 (6.3%) and 4 (6.5%) patients, respectively, had systolic blood pressure ≥160 mmHg and / or diastolic blood pressure ≥100 mmHg.
[0437] The incidence of gastrointestinal-related events was low, including diarrhea (5 [4.0%] patients received sorapinib, 0 patients received placebo), vomiting (3 [2.4%] patients received sorapinib, 1 [1.6%] patients received placebo), and nausea (3 [2.4%] patients received sorapinib, 2 [3.2%] patients received placebo).
[0438] This study post-hoclygated platelet responses in five subgroups of patients who had previously received TPO / TPO-RA therapy. Analysis, including those who have received only TPO treatment, those who have received only TPO-RA treatment, those who have received both TPO and TPO-RA treatment, and those who have received TPO / TPO-RA treatment regimens include one or more drugs. Of the 134 (71.3%) patients (solepinib, 94; placebo, 40), all had previously received TPO / TPO-RA treatment. Among these, the number of patients receiving TPO-only treatment, TPO-RA-only treatment, both TPO and TPO-RA treatment, one or more TPO / TPO-RA drugs, and ≥2 drugs in the two groups (solepinib vs. placebo) were 29 vs. 8, 34 vs. 19, 31 vs. 13, 51 vs. 16, and 43 vs. 24, respectively. These patients had previously received five TPO / TPO-RA treatments, including recombinant human thrombopoietin (81, 60.4%), eltrombopag (73, 54.5%), hetrombopag (28, 20.9%), avatrombopag (28, 20.9%), and romiplostim (10, 7.5%). Primary efficacy data are shown in Table 7. Compared with the placebo group, the solepinib group had significantly higher sustained response and overall response rates in patients who had previously received TPO / TPO-RA treatment (46.8% vs. 0%, 68.1% vs. 7.5%, respectively; all p < 0.0001). Compared with the placebo group, the sustained response rates in the TPO-only subgroup, TPO-RA-only subgroup, and both TPO and TPO-RA subgroup were 58.6% vs 0, 47.1% vs 0, and 35.5% vs 0%, respectively; the overall response rates were 72.4% vs 25.0%, 73.5% vs 5.3%, and 58.1% vs 0, respectively (all p < 0.05). This further demonstrates the significant efficacy of solepinib in platelet response in these subgroups. Furthermore, the results indicate that, compared with the subgroups treated with both TPO and TPO-RA, the TPO-only or TPO-RA-only subgroups showed a greater trend towards improved sustained and overall response benefits with solepinib. Furthermore, compared with placebo, solepinib significantly improved sustained response rate (51.0% vs 0; 41.9% vs 0) and overall response rate (70.6% vs 12.5%; 65.1% vs 4.2%) in the subgroup that had previously received one or more TPO / TPO-RA regimens (all p < 0.0001).
[0439] For patients with primary ITP who have previously received TPO / TPO-RA therapy, solepilanib has a significant and sustained effect in increasing platelet count, regardless of the type and number of TPO / TPO-RA treatments, even for patients who have received ≥2 types of TPO / TPO-RA therapy before starting solepilanib.
[0440] Table 3: Baseline Characteristics (ITT Analysis Set)
[0441] Data are presented as median (range) or n (%). ECOG = Eastern Cooperative Oncology Group; ITP = Immune Thrombocytopenic Pulmonary Disease; IVIG = Intravenous Immunoglobulin; TPO = Thrombopoietin; TPO-RA = Thrombopoietin Receptor Agonist; WHO = World Health Organization.
[0442] This summary reviews the types of anti-ITP medications and the number of previous surgeries. TPO and TPO-RA are considered in the same line of treatment. Additionally, splenectomy and splenic artery embolization are also considered in the same line of treatment. † Almost all medications in the "Other" category are traditional Chinese medicine or blinded therapy.
[0443] Table 4: Summary of primary and secondary therapeutic endpoints
[0444] Data are presented as n (%), % (95% CI), least squares mean (SE) (for bleeding scales), or median (IQR) (for response time). NA = Not applicable.
[0445] No emergency treatment was administered during the treatment period. † Results were obtained from patients who initially signed ICF 3.0 or later and responded.
[0446] Table 5: Average variation in SF-36 scores.
[0447]
[0448] Abbreviations: LS = Least Squares; SE = Standard Error.
[0449] Note: For each scale, statistical comparisons between the two treatment groups were based on longitudinal repeated measures analysis using a mixed-effects model. The model included fixed categorical effects of the treatment groups, time points (weeks 12 and 24), and the interaction between the treatment groups and time points, as well as the continuous fixed covariate of baseline scores.
[0450] Table 6: Adverse events reported during treatment by 10% or more of patients (safety analysis set)
[0451] Note: Data is in n (%). Lists all grades of TEAEs occurring in ≥10% of patients in each group.
[0452] Table 7. Key efficacy data for patients in the intention-to-treat population.
[0453] Table 7: Data are presented as n (%) or % (95% CI), or as otherwise specified. The Clopper-Pearson method was used to calculate the exact 95% CI for each group's response rate; the Cochran-Mantel-Haenszel test was used to analyze the difference in response rates between the two groups.
Claims
1. A method of treating immune thrombocytopenic purpura (ITP) in an individual in need, the method comprising administering a daily dose of about 100-600 mg (optionally about 100-400 mg, about 300-500 mg, about 100 mg, about 200 mg, about 300 mg, about 400 mg, about 500 mg, or about 600 mg) or sufficient to induce an AUC tau,ss Solepinib or a pharmaceutically acceptable salt thereof shall be administered to an individual at a dose of approximately 600–5000 h × ng / mL (optionally approximately 600–800, approximately 1000–1300, approximately 1900–2200 or approximately 2900–3200 h × ng / mL, optional approximately 650–670, approximately 1145–1165, approximately 2055–2175 or approximately 3055–3075 h × ng / mL, optional approximately 661, approximately 1156, approximately 2067 or approximately 3065 h × ng / mL).
2. The method of claim 1, wherein the ITP is primary ITP.
3. The method of any one of claims 1-2, wherein the ITP is newly diagnosed ITP, persistent ITP, or chronic ITP.
4. The method of any one of claims 1-2, wherein the individual has relapsed or refractory ITP.
5. The method of any one of claims 1-4, wherein the individual has previously received at least one prior anti-ITP treatment.
6. The method of any one of claims 1-5, wherein the individual has an inadequate response to or intolerance to at least one prior anti-ITP treatment or has relapsed after at least one prior anti-ITP treatment.
7. The method of any one of claims 5-6, wherein the at least one prior anti-ITP treatment is one, two, three, four, five, six, seven, eight or more prior anti-ITP treatments.
8. The method of any one of claims 5-7, wherein the at least one prior anti-ITP treatment comprises at least one of first-line anti-ITP treatment, second-line anti-ITP treatment, third-line anti-ITP treatment, and further treatment.
9. The method of any one of claims 5-8, wherein the at least one prior anti-ITP treatment comprises one or more treatments selected from: corticosteroids, intravenous immunoglobulin therapy (IVIg), anti-D immunoglobulin, thrombopoietin (TPO) therapy, thrombopoietin receptor agonist (TPO-RA) therapy, anti-CD20 antibody therapy, immunosuppressants, vinca alkaloids, alenzab, danazol, dapsone, platelet transfusion, danazol / stanozolol, caffeic acid, IL-11, traditional Chinese medicine, and splenectomy.
10. The method of any one of claims 5-9, wherein the at least one prior anti-ITP treatment comprises TPO treatment and / or TPO-RA treatment.
11. The method of any one of claims 5-9, wherein the at least one prior anti-ITP treatment comprises TPO treatment or TPO-RA treatment.
12. The method of any one of claims 5-9, wherein the at least one prior anti-ITP treatment comprises both TPO treatment and TPO-RA treatment.
13. The method of any one of claims 5-10, wherein the at least one prior anti-ITP treatment comprises only one drug of TPO / TPO-RA treatment.
14. The method of any one of claims 5-10, wherein the at least one prior anti-ITP treatment comprises at least two drugs of TPO / TPO-RA treatment.
15. The method of any one of claims 5-10, wherein the at least one prior anti-ITP treatment comprises one or more active agents selected from recombinant human thrombopoietin, eltrombopag, hetrombopag, avatrombopag, and romistatin.
16. The method of any one of claims 5-15, wherein the at least one prior anti-ITP treatment comprises anti-CD20 antibody treatment.
17. The method of any one of claims 5-16, wherein the at least one prior anti-ITP treatment comprises splenectomy.
18. The method of any one of claims 5-17, wherein the at least one prior anti-ITP treatment includes emergency treatment.
19. The method of any one of claims 1-18, wherein the individual has a platelet count of less than 30 × 10⁻⁶ prior to treatment with solepinib or a pharmaceutically acceptable salt thereof. 9 / L.
20. The method of any one of claims 1-19, wherein the individual has a platelet count of less than 15 × 10⁻⁶ prior to treatment with sorapinib or a pharmaceutically acceptable salt thereof. 9 / L.
21. The method of any one of claims 1-19, wherein the individual has a platelet count greater than 15 × 10⁻⁶ prior to treatment with sorapinib or a pharmaceutically acceptable salt thereof. 9 / L and less than 30×10 9 / L.
22. The method of any one of claims 1-21, wherein the individual has a hemoglobin level ≥100 g / L and >1.5 × 10⁻⁶ g / L prior to treatment with sorapinib or a pharmaceutically acceptable salt thereof. 9 Neutrophil count / L.
23. The method of any one of claims 1-22, wherein the individual has a WHO bleeding scale score of 0 or 1 prior to treatment with sorapinib or a pharmaceutically acceptable salt thereof, and / or has had chronic ITP for ≥3 years.
24. The method of any one of claims 1-23, wherein the individual is unresponsive to sorapinib or a pharmaceutically acceptable salt thereof during the first 12 weeks of treatment.
25. The method of any one of claims 1-24, wherein the individual is an adult.
26. The method of any one of claims 1-25, wherein the individual is of Asian descent.
27. The method of any one of claims 1-25, wherein the individual is a non-Asian population, optionally an American population, a European population, a Caucasian population, an Oceanian population, and / or an African population.
28. The method of any one of claims 1-27, wherein solepinib or a pharmaceutically acceptable salt thereof is sufficient to cause AUC tau,ss A dose of approximately 2067 h × ng / mL was administered.
29. The method of any one of claims 1-27, wherein solepinib or a pharmaceutically acceptable salt thereof is administered at a daily dose of about 300 mg.
30. The method of any one of claims 1-27, wherein solepinib or a pharmaceutically acceptable salt thereof is administered at a daily dose of about 500 mg.
31. The method of any one of claims 1-30, wherein during treatment, the dose of sorapinib or a pharmaceutically acceptable salt thereof is reduced in the following manner: (1) During treatment, the individual's platelet count is ≥250 ×10⁻⁶. 9 Platelets count of approximately 400 × 10⁹ for about two weeks, or a platelet count ≥ 400 × 10⁹ at any time. 9 / L; (2) Individuals who received concurrent anti-ITP therapy during treatment and whose platelet count was ≥100×10⁻⁶. 9 / L lasting approximately 4 weeks, or a platelet count ≥250×10 9 / L lasts for about 2 weeks; or (3) Individuals experience drug-related adverse events.
32. The method of any one of claims 1-31, wherein the dose is administered once daily (QD) or in divided doses, such as twice daily (BID).
33. The method of any one of claims 1-32, wherein solepinib or a pharmaceutically acceptable salt thereof is administered orally.
34. The method of any one of claims 1-33, wherein solepinib or a pharmaceutically acceptable salt thereof is administered as a monotherapy or in combination with one or more other therapeutic agents.
35. The method of any one of claims 1-34, wherein solepinib or a pharmaceutically acceptable salt thereof is administered in combination with concomitant anti-ITP treatment.
36. The method of any one of claims 1-35, wherein the individual has been receiving a stable dose of concomitant anti-ITP treatment.
37. The method of any one of claims 34-36, wherein the other therapeutic agent or combined anti-ITP treatment is a combination drug selected from: corticosteroids, TPO-RA, danazol and immunosuppressants.
38. The method of any one of claims 34-36, wherein the other therapeutic agent or combined anti-ITP treatment is not an emergency treatment.
39. The method of any one of claims 1-38, wherein the individual, after treatment with sorapinib or a pharmaceutically acceptable saline thereof, has a sustained response (including an improved sustained response rate), an improved overall response (including an improved overall response rate), an improved platelet count, a rapid onset of action or an improved response time, a reduction in the incidence or severity of bleeding, including a decrease in WHO Bleeding Scale score, a reduction in the frequency of ≥ grade 3 bleeding, improved hemoglobin levels, long-term remission of ITP, improved health-related quality of life (HRQoL), reduced use of emergency treatment and / or reduction or interruption of baseline concomitant anti-ITP treatment, and / or is safe and tolerable over time, with an optional low risk of gastrointestinal toxicity.
40. The method of any one of claims 1-39, wherein a pharmaceutically acceptable salt of solepinib is solepinib acetate.
41. An article comprising: Solepinib or its pharmaceutically acceptable salts, and The package insert includes instructions for the use of sorapinib or a pharmaceutically acceptable salt thereof for the treatment of immune thrombocytopenic purpura (ITP) in an individual in need, wherein the instructions indicate that sorapinib or a pharmaceutically acceptable salt thereof is administered in accordance with the method defined in any one of claims 1-40.
Citation Information
Patent Citations
The salts of a compound and the crystalline forms thereof
WO2019037737A1
